Exporter
Liste modèle des médicaments essentiels
Trouvé 1312 recommandations pour 635 médicaments et 135 équivalents thérapeutiques
Les recommandations supprimées et les demandes rejetées sont affichées. Les cacher.
-
BCG vaccine Informations générales
SectionRecommendations for all immunization programmes- All vaccines should comply with the WHO requirements for biological substances.
Indications -
Japanese encephalitis vaccine Informations générales
SectionRecommendations for certain regions- All vaccines should comply with the WHO requirements for biological substances.
-
Medicines for COVID-19 Informations générales
SectionMedicines for COVID-19- Refer to WHO living guidelines
Indications -
Abacavir Informations générales
SectionAntiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors- Oral > Solid: 300 mg tablet (as sulfate)
-
Abacavir + lamivudine Informations générales
SectionFixed-dose combinations of antiretrovirals- Oral > Solid: 120 mg (as sulfate) + 60 mg tablet (dispersible, scored)
-
Abacavir + lamivudine + lopinavir + ritonavir Informations générales
SectionFixed-dose combinations of antiretrovirals- Oral > Solid: 30 mg + 15 mg + 40 mg + 10 mg capsule containing oral granules
-
Abemaciclib Informations générales
SectionTargeted therapiesIndicationsTherapeutic equivalent to palbociclib pour Other specified malignant neoplasms of breast -
Abiraterone Informations générales
SectionHormones and antihormones- Oral > Solid: 250 mg; 500 mg
Indications -
Acamprosate calcium Informations générales
SectionMedicines for alcohol use disorders- Oral > Solid > tablet: 333 mg
Indications -
Acetazolamide Informations générales
SectionOphthalmological preparations > Miotics and antiglaucoma medicines- Oral > Solid: 250 mg
Indications -
Acetic acid Informations générales
SectionEar, nose and throat medicines [c]- Local > Otological > drops: 2% in alcohol
Indications -
Acetylcysteine Informations générales
SectionAntidotes and other substances used in poisonings > Specific- Parenteral > General injections > IV: 200 mg per mL in 10 mL ampoule
- Oral > Liquid: 10%; 20%
-
Acetylsalicylic acid Informations générales
SectionAntimigraine medicines > For treatment of acute attack- Oral > Solid: 300 to 500 mg
IndicationsSectionAnti-platelet medicines- Oral > Solid: 100 mg
IndicationsSectionMedicines for juvenile joint diseases- Oral > Solid: 100 to 500 mg
- Local > Rectal > Suppository: 50 to 150 mg
SectionNon-opioids and non-steroidal anti-inflammatory medicines (NSAIMs)- Oral > Solid: 100 to 500 mg
- Local > Rectal > Suppository: 50 to 150 mg
Indications -
Acetylsalicylic acid + atorvastatin + ramipril Informations générales
SectionFixed-dose combinations for prevention of atherosclerotic cardiovascular disease- Oral > Solid > tablet: 100 mg + 20 mg + 2.5 mg; 100 mg + 20 mg + 5 mg; 100 mg + 20 mg + 10 mg; 100 mg + 40 mg + 2.5 mg; 100 mg + 40 mg + 5 mg; 100 mg + 40 mg + 10 mg
-
Acetylsalicylic acid + simvastatin + ramipril + atenolol + hydrochlorothiazide Informations générales
SectionFixed-dose combinations for prevention of atherosclerotic cardiovascular disease- Oral > Solid > tablet: 100 mg + 20 mg + 5 mg + 50 mg + 12.5 mg
-
Aciclovir Informations générales
SectionAntiherpes medicines- Parenteral > General injections > IV: 250 mg in vial powder for injection (as sodium salt)
- Oral > Liquid: 200 mg per 5 mL
- Oral > Solid: 200 mg tablet
IndicationsSectionOphthalmological preparations > Anti-infective agents- Local > Ophthalmological > Ointment: 3% w/w
Indications -
Aclidinium Informations générales
SectionAntiasthmatic and medicines for chronic obstructive pulmonary diseaseIndicationsTherapeutic equivalent to tiotropium bromide pour Chronic obstructive pulmonary disease -
Activated charcoal Informations générales
SectionAntidotes and other substances used in poisonings > Non-specific- Oral > Other: powder
-
Adalimumab Informations générales
SectionImmunomodulators for non-malignant disease- Parenteral > General injections > SC: 40 mg per 0.8 mL; 40 mg per 0.4 mL; 10 mg per 0.2 mL; 20 mg per 0.4 mL
SectionMedicines for juvenile joint diseases- Parenteral > General injections > SC: 40 mg per 0.8 mL; 40 mg per 0.4 mL; 10 mg per 0.2 mL; 20 mg per 0.4 mL
Indications -
Afatinib Informations générales
SectionTargeted therapiesIndicationsTherapeutic equivalent to erlotinib pour Other specified malignant neoplasms of bronchus or lung -
Albendazole Informations générales
SectionIntestinal anthelminthics- Oral > Solid > tablet: 400 mg (chewable, scored)
SectionCysticidal medicines- Oral > Solid > tablet: 400 mg (chewable, scored); 200 mg (chewable)
SectionAntifilarials- Oral > Solid > tablet: 400 mg (chewable, scored)
Indications -
Alcohol based hand rub Informations générales
SectionDisinfectants- Local > Topical > Solution: 80% v/v ethanol; 75% v/v isopropyl alcohol
Indications -
Alcuronium Informations générales
SectionMuscle relaxants (peripherally-acting) and cholinesterase inhibitors- Parenteral > General injections > IV: 5 mg per mL in 2 mL ampoule (alcuronium chloride)
Indications -
Alfacalcidol Informations générales
SectionMedicines for endocrine disorders- Oral > Liquid: 2 µg per mL
- Oral > Solid > capsule: 0.25 µg; 1 µg
-
All-trans retinoic acid Informations générales
SectionTargeted therapies- Oral > Solid: 10 mg capsule
-
Allopurinol Informations générales
SectionMedicines used to treat gout- Oral > Solid: 100 mg
IndicationsSectionSupportive medicines- Oral > Solid: 100 mg; 300 mg
Indications -
Alteplase Informations générales
SectionThrombolytic medicines- Parenteral > General injections > IV: 10 mg in vial powder for injection; 20 mg in vial powder for injection; 50 mg in vial powder for injection
Indications -
Amidotrizoate Informations générales
SectionDiagnostic agents > Radiocontrast media- Parenteral > General injections > unspecified: 140 to 420 mg iodine per mL in 20 mL ampoule (as sodium or meglumine salt)
Indications -
Amikacin Informations générales
SectionOphthalmological preparations > Anti-infective agentsIndicationsTherapeutic equivalent to gentamicin pour Other specified conjunctivitis Therapeutic equivalent to gentamicin pour Infectious blepharitisSectionAntituberculosis medicines- Parenteral > General injections > unspecified: 250 mg per mL in 2 mL vial (as sulfate)
IndicationsSectionAccess group antibiotics- Parenteral > General injections > unspecified: 250 mg per mL in 2 mL vial (as sulfate); 50 mg per mL in 2 mL vial (as sulfate)
- Parenteral > General injections > unspecified: 250 mg per mL in 2 mL vial (as sulfate)
IndicationsPremier choix
Neutropenia (high-risk) co-prescrite avec cefotaxime Inflammatory and other diseases of prostate (severe) co-prescrite avec cefotaxime Acute pyelonephritis (severe) co-prescrite avec ceftriaxone Inflammatory and other diseases of prostate (severe) co-prescrite avec ceftriaxone Acute pyelonephritis (severe)Second choix
co-prescrite avec cloxacillin Sepsis without septic shock -
Amiloride Informations générales
-
Amiodarone Informations générales
SectionAntiarrhythmic medicines- Parenteral > General injections > IV: 50 mg per mL in 3 ampoule (hydrochloride)
- Oral > Solid: 100 mg (hydrochloride); 200 mg (hydrochloride); 400 mg (hydrochloride)
Indications -
Amitriptyline Informations générales
SectionMedicines for other common symptoms in palliative care- Oral > Solid: 25 mg; 10 mg; 75 mg
IndicationsSectionMedicines for depressive disorders- Oral > Solid: 25 mg; 75 mg
Indications -
Amlodipine Informations générales
SectionAntihypertensive medicines- Oral > Solid: 5 mg (as maleate, mesylate or besylate)
Indications -
Amodiaquine Informations générales
SectionAntimalarial medicines > For curative treatment- Oral > Solid: 153 mg (as hydrochloride); 200 mg (as hydrochloride)
-
Amodiaquine + sulfadoxine + pyrimethamine Informations générales
SectionAntimalarial medicines > For chemoprevention- Oral > Solid: 76.5 mg (as hydrochloride) [3] + 250 mg + 12.5 mg [1] dispersible tablets in co-package; 153 mg (as hydrochloride) [3] + 500 mg + 25 mg [1] dispersible tablets in co-package
Indications -
Amoxicillin Informations générales
SectionAccess group antibiotics- Oral > Liquid: 125 mg per 5 mL (as trihydrate) powder for oral liquid; 250 mg per 5 mL (as trihydrate) powder for oral liquid
- Parenteral > General injections > unspecified: 250 mg in vial (as sodium) powder for injection; 500 mg in vial (as sodium) powder for injection; 1 g in vial (as sodium) powder for injection
- Oral > Solid > dispersible tablet: 250 mg (scored) (as trihydrate); 500 mg (scored) (as trihydrate)
- Oral > Solid > dosage form: 250 mg (as trihydrate); 500 mg (as trihydrate)
- Oral > Liquid: 125 mg per 5 mL (anhydrous) powder for oral liquid; 250 mg per 5 mL (anhydrous) powder for oral liquid
- Oral > Solid > dosage form: 250 mg (as trihydrate); 500 mg (as trihydrate); 1 g (as trihydrate)
IndicationsPremier choix
Bacterial pneumonia (Community-acquired pneumonia - mild to moderate) Acute malnutrition in infants, children or adolescents (uncomplicated) [children] Acute malnutrition in infants, children or adolescents (complicated) [children] Acute pharyngitis Chronic obstructive pulmonary disease with acute exacerbation Periapical abscess without sinus Acute otitis media Acute sinusitis co-prescrite avec gentamicin Bacterial pneumonia (Community-acquired pneumonia - severe) [children] co-prescrite avec gentamicin Sepsis without septic shockSecond choix
Bacterial meningitisAutres indications -
Amoxicillin + clavulanic acid Informations générales
SectionAccess group antibiotics- Parenteral > General injections > IV: 500 mg (as sodium salt) + 100 mg (as potassium salt) powder for injection; 1000 mg (as sodium salt) + 200 mg (as potassium salt) powder for injection
- Oral > Liquid: 125 mg (as trihydrate) + 31.25 mg (as potassium salt) / 5 mL powder for oral liquid; 250 mg (as trihydrate) + 62.5 mg (as potassium salt) / 5 mL powder for oral liquid
- Oral > Solid > dispersible tablet: 200 mg (as trihydrate) + 28.5 mg (as potassium salt); 250 mg (as trihydrate) + 62.5 mg (as potassium salt)
- Oral > Solid > tablet: 500 mg (as trihydrate) + 125 mg (as potassium salt); 875 mg (as trihydrate) + 125 mg (as potassium salt)
- Oral > Solid > tablet: 500 mg (as trihydrate) + 125 mg (as potassium salt)
IndicationsPremier choix
Peritoneal abscess (mild-moderate) Neutropenia (low-risk) Other specified pneumonia (Hospital-acquired pneumonia) Infectious cystitis Chronic obstructive pulmonary disease with acute exacerbation Peritonitis (mild-moderate) Acute sinusitis Bacterial cellulitis, erysipelas or lymphangitis Bacterial pneumonia (Community-acquired pneumonia - severe) [children]Autres indicationsSectionAntituberculosis medicines- Oral > Liquid: 250 mg (as trihydrate) + 62.5 mg (as potassium salt) / 5 mL powder for oral liquid
- Oral > Solid > tablet: 500 mg (as trihydrate) + 125 mg (as potassium salt)
Indications -
Amphotericin B Informations générales
SectionAntifungal medicines- Parenteral > General injections > IV: 50 mg in vial powder for injection (liposomal complex); 50 mg in vial powder for injection (as sodium deoxycholate)
SectionAntileishmaniasis medicines- Parenteral > General injections > IV: 50 mg in vial powder for injection (liposomal complex); 50 mg in vial powder for injection (as sodium deoxycholate)
Indications -
Ampicillin Informations générales
SectionAccess group antibiotics- Parenteral > General injections > unspecified: 500 mg in vial (as sodium salt) powder for injection; 1 g in vial (as sodium salt) powder for injection
- Oral > Liquid: 125 mg per 5 mL (anhydrous) powder for oral suspension
- Oral > Solid: 250 mg (anhydrous); 500 mg (anhydrous)
IndicationsPremier choix
co-prescrite avec gentamicin Peritoneal abscess (severe) co-prescrite avec gentamicin Sepsis without septic shock co-prescrite avec gentamicin Peritoneal abscess (mild-moderate) co-prescrite avec gentamicin Peritonitis (severe) co-prescrite avec gentamicin Acute malnutrition in infants, children or adolescents (complicated) [children] co-prescrite avec gentamicin Peritonitis (mild-moderate) co-prescrite avec gentamicin Bacterial pneumonia (Community-acquired pneumonia - severe) [children]Second choix
Bacterial meningitisAutres indications -
Anakinra Informations générales
SectionMedicines for juvenile joint diseases- Parenteral > General injections > SC: 100 mg per 0.67 mL in pre-filled syringe
Indications -
Anastrozole Informations générales
SectionHormones and antihormones- Oral > Solid: 1 mg tablet
-
Anidulafungin Informations générales
SectionAntifungal medicinesIndicationsTherapeutic equivalent to micafungin pour Systemic or invasive candidosis -
Ansuvimab Informations générales
SectionMedicines for Ebola virus disease- Parenteral > General injections > IV: 400 mg powder for injection
Indications -
Anti-D immunoglobulin Informations générales
SectionHuman immunoglobulins- Parenteral > General injections > IV: 250 µg in single-dose vial
- Parenteral > General injections > IM: 250 µg in single-dose vial
-
Anti-rabies immunoglobulin Informations générales
SectionHuman immunoglobulins- Parenteral > General injections > IM: 150 IU per mL in vial
- Parenteral > Locoregional injections > Other: 150 IU per mL in vial
Indications -
Anti-rabies virus monoclonal antibodies Informations générales
SectionImmunologicals > Sera, immunoglobulins and monoclonal antibodies- Parenteral > Locoregional injections > Intradermal: 40 IU per mL in 1.25 mL vial (human); 40 IU per mL in 2.5 mL vial (human); 100 IU per mL in 2.5 mL vial (human); 300 IU per mL in 10 mL vial (murine); 600 IU per mL in 1 mL vial (murine); 600 IU per mL in 2.5 mL vial (murine); 600 IU per mL in 5 mL vial (murine)
Indications -
Anti-tetanus immunoglobulin Informations générales
SectionHuman immunoglobulins- Parenteral > General injections > IM: 500 IU in vial
Indications -
Antirabies hyperimmune serum Informations générales
SectionImmunologicals > Sera, immunoglobulins and monoclonal antibodies- Parenteral > General injections > unspecified: 1000 IU in 5 mL ampoule
Indications -
Antivenom immunoglobulin Informations générales
SectionImmunologicals > Sera, immunoglobulins and monoclonal antibodies- Parenteral > General injections > IV:
-
Antivenom sera Informations générales
SectionImmunologicals > Sera, immunoglobulins and monoclonal antibodies- Parenteral > General injections > IV:
-
Apixaban Informations générales
SectionMedicines affecting coagulationIndicationsTherapeutic equivalent to dabigatran pour Venous thromboembolism Therapeutic equivalent to dabigatran pour Other specified atrial fibrillation -
Aprepitant Informations générales
SectionAntiemetic medicines- Oral > Liquid: 125 mg powder for oral suspension (in sachet)
- Oral > Solid: 80 mg; 125 mg; 165 mg
Indications -
Aripiprazole Informations générales
SectionMedicines for psychotic disordersIndicationsTherapeutic equivalent to risperidone pour Schizophrenia or other primary psychotic disorders -
Arsenic trioxide Informations générales
SectionCytotoxic medicines- Parenteral > General injections > IV: 1 mg per mL concentrate for solution for infusion; 2 mg per mL concentrate for solution for infusion
-
Artemether Informations générales
SectionAntimalarial medicines > For curative treatment- Parenteral > General injections > IM: 80 mg per mL in 1 mL ampoule (oily injection)
-
Artemether + lumefantrine Informations générales
SectionAntimalarial medicines > For curative treatment- Oral > Solid: 20 mg + 120 mg tablet; 20 mg + 120 mg dispersible tablet
-
Artesunate Informations générales
SectionAntimalarial medicines > For curative treatment- Parenteral > General injections > IV: 60 mg in ampoule containing anhydrous artesunic acid with a separate ampoule of 5% sodium bicarbonate solution
- Oral > Solid: 50 mg tablet
- Local > Rectal > Other: 50 mg capsules; 200 mg capsules; 100 mg capsules
-
Artesunate + amodiaquine Informations générales
SectionAntimalarial medicines > For curative treatment- Oral > Solid: 25 mg + 67.5 mg tablet; 50 mg + 135 mg tablet; 100 mg + 270 mg tablet
-
Artesunate + mefloquine Informations générales
SectionAntimalarial medicines > For curative treatment- Oral > Solid: 25 mg + 55 mg tablet; 100 mg + 220 mg tablet
-
Artesunate + pyronaridine tetraphosphate Informations générales
SectionAntimalarial medicines > For curative treatment- Oral > Solid: 60 mg + 180 mg tablet; 20 mg + 60 mg granules
-
Ascorbic acid Informations générales
SectionVitamins and minerals- Oral > Solid: 50 mg
Indications -
Asparaginase Informations générales
SectionCytotoxic medicines- Powder for injection: 10 000 IU in vial.
- Parenteral > General injections > unspecified: 10000 IU in vial powder for injection
-
Atazanavir Informations générales
SectionAntiretrovirals > Protease inhibitors- Oral > Solid: 100 mg (as sulfate); 300 mg (as sulfate)
-
Atazanavir + ritonavir Informations générales
SectionAntiretrovirals > Protease inhibitors- Oral > Solid: 300 mg (as sulfate) + 100 mg tablet (heat stable)
-
Atenolol Informations générales
SectionAntianginal medicines- Oral > Solid: 50 mg; 100 mg
IndicationsSectionAntihypertensive medicines- Oral > Solid: 50 mg; 100 mg
Indications -
Atezolizumab Informations générales
SectionImmunomodulators- Parenteral > General injections > IV: 1.2 g per 20 mL concentrate solution for infusion
IndicationsOther specified malignant neoplasms of bronchus or lung Therapeutic equivalent to pembrolizumab pour Other specified malignant neoplasms of bronchus or lung -
Atoltivimab + maftivimab + odesivimab Informations générales
SectionMedicines for Ebola virus disease- Parenteral > General injections > IV: 241.7 mg + 241.7 mg + 241.7 mg in 14.5 mL vial
Indications -
Atorvastatin Informations générales
SectionLipid-lowering agentsIndicationsTherapeutic equivalent to simvastatin pour Mixed hyperlipidaemia Therapeutic equivalent to simvastatin pour Coronary atherosclerosis -
Atorvastatin + perindopril + amlodipine Informations générales
SectionFixed-dose combinations for prevention of atherosclerotic cardiovascular disease- Oral > Solid > tablet: 20 mg + 5 mg + 5 mg; 20 mg + 10 mg + 10 mg; 40 mg + 5 mg + 5 mg; 40 mg + 10 mg + 10 mg
-
Atracurium Informations générales
SectionMuscle relaxants (peripherally-acting) and cholinesterase inhibitors- Parenteral > General injections > IV: 10 mg per mL (besylate)
Indications -
Atropine Informations générales
SectionAntidotes and other substances used in poisonings > Specific- Parenteral > General injections > unspecified: 1 mg in 1 mL ampoule (atropine sulfate)
SectionPreoperative medication and sedation for short-term procedures- Parenteral > General injections > unspecified: 1 mg in 1 mL ampoule (atropine sulfate)
SectionDiagnostic agents > Ophthalmic medicinesIndicationsTherapeutic equivalent to tropicamide pour Cycloplegic drugSectionOphthalmological preparations > Mydriatics- Local > Ophthalmological > Solution (eye drops): 0.1% (sulfate); 0.5% (sulfate); 1% (sulfate)
Indications -
Axicabtagene ciloleucel Informations générales
SectionAntineoplastics and supportive medicines- Cell suspension for infusion: 2 × 10*6 anti-CD19 CAR-positive viable T-cells per kg of body weight.
Indications -
Azacitidine Informations générales
SectionCytotoxic medicines- Parenteral > General injections > IV: 100 mg in vial powder for injection
Indications -
Azathioprine Informations générales
SectionImmunomodulators for non-malignant disease- Parenteral > General injections > IV: 50 mg in vial powder for injection (as sodium salt); 100 mg in vial powder for injection (as sodium salt)
- Oral > Liquid: 10 mg per mL
- Oral > Solid > tablet: 25 mg; 50 mg (scored)
- Oral > Solid > tablet: 50 mg (scored)
SectionDisease-modifying anti-rheumatic drugs (DMARDs)- Oral > Solid > tablet: 50 mg (scored)
-
Azithromycin Informations générales
SectionOphthalmological preparations > Anti-infective agents- Local > Ophthalmological > Solution (eye drops): 1.5% eye drops
IndicationsSectionWatch group antibiotics- Oral > Liquid: 200 mg per 5 mL (anhydrous) powder for oral liquid
- Oral > Solid > dosage form: 250 mg (anhydrous); 500 mg (anhydrous)
IndicationsPremier choix
Chlamydia trachomatis Typhoid fever Yaws Paratyphoid fever Cholera Cholera [children] Trachoma co-prescrite avec ceftriaxone Gonococcal infectionSecond choix
Infectious gastroenteritis or colitis without specification of infectious agent co-prescrite avec cefixime Gonococcal infection -
Aztreonam Informations générales
SectionReserve group antibiotics- Parenteral > General injections > unspecified: 1 g in vial powder for injection; 2 g in vial powder for injection
Indications -
Barium sulfate Informations générales
SectionDiagnostic agents > Radiocontrast media- Oral > Liquid: Aqueous suspension
Indications -
Beclometasone Informations générales
SectionAntiasthmatic and medicines for chronic obstructive pulmonary disease- Respiratory > Inhalation > aerosol: 50 µg per dose (dipropionate); 250 µg per dose (dipropionatae)
Indications -
Beclometasone + formoterol Informations générales
SectionAntiasthmatic and medicines for chronic obstructive pulmonary diseaseIndicationsTherapeutic equivalent to budesonide + formoterol pour Asthma -
Bedaquiline Informations générales
SectionAntituberculosis medicines- Oral > Solid: 100 mg tablet; 20 mg tablet
Indications -
Bendamustine Informations générales
SectionCytotoxic medicines- Parenteral > General injections > unspecified: 45 mg per 0.5 mL; 180 mg per 2 mL
-
Benzathine benzylpenicillin Informations générales
SectionAccess group antibiotics- Parenteral > General injections > IM: 1.2 million IU in vial (≈ 900 mg) powder for injection; 2.4 million IU in vial (≈ 1.8 g) powder for injection
IndicationsAutres indications -
Benznidazole Informations générales
SectionAmerican trypanosomiasis- Oral > Solid > tablet: 100 mg (scored); 50 mg (scored); 12.5 mg
Indications -
Benzoic acid + salicylic acid Informations générales
SectionDermatological medicines > Antifungal medicines- Local > Topical > Cream: 6% + 3%
- Local > Topical > Ointment: 6% + 3%
Indications -
Benzoyl peroxide Informations générales
SectionDermatological medicines > Medicines affecting skin differentiation and proliferation- Local > Topical > Cream: 5%
- Local > Topical > Lotion: 5%
Indications -
Benzyl benzoate Informations générales
SectionDermatological medicines > Scabicides and pediculicides- Local > Topical > Lotion: 25%
Indications -
Benzylpenicillin Informations générales
SectionAccess group antibiotics- Parenteral > General injections > unspecified: 600 mg in vial powder for injection (=1 million IU as sodium or potassium salt); 3 g in vial powder for injection (=5 million IU as sodium or potassium salt)
- Parenteral > General injections > unspecified: 600 mg in vial powder for injection (= 1 million IU as sodium or potassium salt); 3 g in vial powder for injection (= 5 million IU as sodium or potassium salt)
IndicationsPremier choix
Congenital syphilis [children] Syphilis co-prescrite avec gentamicin Sepsis without septic shock co-prescrite avec gentamicin Acute malnutrition in infants, children or adolescents (complicated) [children] co-prescrite avec gentamicin Bacterial pneumonia (Community-acquired pneumonia - severe) [children]Second choix
Bacterial meningitisAutres indications -
Betamethasone Informations générales
SectionDermatological medicines > Anti-inflammatory and antipruritic medicines- Local > Topical > Cream: 0.1% (as valerate)
- Local > Topical > Ointment: 0.1% (as valerate)
-
Bevacizumab Informations générales
SectionOphthalmological preparations > Anti-vascular endothelial growth factor (VEGF) preparations- Parenteral > Locoregional injections > Intravitreal: 25 mg per mL
Indications -
Bicalutamide Informations générales
SectionHormones and antihormones- Oral > Solid: 50 mg
Indications -
Binimetinib Informations générales
SectionTargeted therapiesIndicationsTherapeutic equivalent to trametinib pour Other specified melanoma of skin -
Biperiden Informations générales
SectionMedicines for parkinsonism- Parenteral > General injections > IV: 5 mg per mL in 1 mL ampoule (lactate)
- Oral > Solid: 2 mg tablet (hydrochloride)
Indications -
Bisacodyl Informations générales
SectionLaxativesIndicationsTherapeutic equivalent to senna pour Constipation -
Bisoprolol Informations générales
SectionAntianginal medicines- Oral > Solid: 1.25 mg; 5 mg
IndicationsSectionMedicines used in heart failure- Oral > Solid: 1.25 mg; 5 mg
IndicationsSectionAntihypertensive medicines- Oral > Solid: 1.25 mg; 5 mg
IndicationsSectionAntiarrhythmic medicines- Oral > Solid: 1.25 mg; 5 mg
Indications -
Bleomycin Informations générales
SectionCytotoxic medicines- Parenteral > General injections > unspecified: 15000 IU in vial (as sulfate)
-
Bortezomib Informations générales
SectionTargeted therapies- Parenteral > General injections > unspecified: 3.5 mg in vial powder for injection
Indications -
Bromocriptine Informations générales
SectionAntiseizure medicines- Oral > Solid: 2.5 mg; 5 mg
IndicationsSectionMedicines for disorders of the pituitary hormone systemIndicationsTherapeutic equivalent to cabergoline pour Other specified benign neoplasm of endocrine glands -
Budesonide Informations générales
SectionAntiasthmatic and medicines for chronic obstructive pulmonary disease- Respiratory > Inhalation > aerosol: 100 µg per dose; 200 µg per dose
IndicationsSectionEar, nose and throat medicines [c]- Local > Nasal > Spray: 100 µg per dose
Indications -
Budesonide + formoterol Informations générales
SectionAntiasthmatic and medicines for chronic obstructive pulmonary disease- Respiratory > Inhalation > dry powder: 100 µg + 6 µg per dose; 200 µg + 6 µg per dose
Indications -
Budesonide + salmeterol Informations générales
SectionAntiasthmatic and medicines for chronic obstructive pulmonary diseaseIndicationsTherapeutic equivalent to budesonide + formoterol pour Asthma -
Bumetanide Informations générales
SectionMedicines used in heart failureIndicationsTherapeutic equivalent to furosemide pour Heart failureSectionDiureticsIndicationsTherapeutic equivalent to furosemide pour Anuria or oliguria Therapeutic equivalent to furosemide pour Oedema -
Bupivacaine Informations générales
SectionLocal anaesthetics- Parenteral > Locoregional injections > Spinal anaesthesia: 0.5% in 4 mL ampoule (hydrochloride) + 7.5% glucose solution
- Parenteral > General injections > unspecified: 0.25% in vial (hydrochloride); 0.5% in vial (hydrochloride)
Indications -
Buprenorphine Informations générales
SectionMedicines for opioid use disordersIndicationsTherapeutic equivalent to methadone pour Opioid dependence -
Bupropion Informations générales
SectionMedicines for nicotine use disorders- Oral > Solid: 150 mg sustained-release (hydrochloride)
Indications -
C1 esterase inhibitor Informations générales
SectionPlasma-derived medicines- Parenteral > General injections > IV: 500 IU in vial powder for injection
Indications -
Cabergoline Informations générales
SectionMedicines for disorders of the pituitary hormone system- Oral > Solid > tablet: 0.5 mg; 1 mg
SectionAntiseizure medicines- Oral > Solid > tablet: 0.5 mg
Indications -
Caffeine citrate Informations générales
SectionMedicines administered to the neonate [c]- Parenteral > General injections > IV: 20 mg per mL (equivalent to 10 mg caffeine base per mL)
- Oral > Liquid: 20 mg per mL (equivalent to 10 mg caffeine base per mL)
Indications -
Calamine Informations générales
SectionDermatological medicines > Anti-inflammatory and antipruritic medicines- Local > Topical > Lotion:
Indications -
Calcipotriol Informations générales
SectionDermatological medicines > Medicines affecting skin differentiation and proliferation- Local > Topical > Cream: 50 µg per mL (0.005%)
- Local > Topical > Lotion: 50 µg per mL (0.005%)
- Local > Topical > Ointment: 50 µg per mL (0.005%)
Indications -
Calcitriol Informations générales
SectionDermatological medicines > Medicines affecting skin differentiation and proliferationIndicationsTherapeutic equivalent to calcipotriol pour Psoriasis of unspecified typeSectionMedicines for endocrine disorders- Oral > Solid > capsule: 0.25 µg; 0.5 µg
-
Calcium Informations générales
SectionVitamins and minerals- Oral > Solid: 500 mg (elemental calcium)
Indications -
Calcium folinate (leucovorin calcium) Informations générales
SectionCytotoxic medicines- Oral > Solid: 15 mg tablet
- Parenteral > General injections > unspecified: 3 mg per mL in 10 mL ampoule
- Parenteral > General injections > unspecified: 3 mg per mL in 10 mL ampoule; 7.5 mg per mL in 2 mL ampoule; 10 mg per mL in 5 mL ampoule
- Oral > Solid > tablet: 15 mg; 5 mg; 25 mg
IndicationsUnspecified malignant neoplasms of ill-defined or unspecified sites Burkitt lymphoma including Burkitt leukaemia Malignant neoplasm metastasis in large intestine Malignant trophoblastic neoplasms of placenta Osteosarcoma of bone and articular cartilage of unspecified sites Malignant neoplasms of rectum Malignant neoplasms of colon -
Calcium gluconate Informations générales
SectionAntidotes and other substances used in poisonings > Specific- Parenteral > General injections > IV: 100 mg per mL in 10 mL ampoule
IndicationsSectionVitamins and minerals- Parenteral > General injections > IV: 100 mg per mL in 10 mL ampoule
Indications -
Canagliflozin Informations générales
SectionOral hypoglycaemic agentsIndicationsTherapeutic equivalent to empagliflozin pour Type 2 diabetes mellitus -
Capecitabine Informations générales
SectionCytotoxic medicines- Oral > Solid > tablet: 150 mg; 500 mg
-
Capreomycin Informations générales
SectionAntituberculosis medicines- Parenteral > General injections > IV: 1000 mg powder for injection (vial)
Indications -
Captopril Informations générales
SectionMedicines used in heart failure- Oral > Solid: 25 mg
Indications -
Carbachol Informations générales
SectionOphthalmological preparations > Miotics and antiglaucoma medicinesIndicationsTherapeutic equivalent to pilocarpine pour Acute angle closure with pupillary block Therapeutic equivalent to pilocarpine pour Ocular hypertension Therapeutic equivalent to pilocarpine pour Primary open-angle glaucoma -
Carbamazepine Informations générales
SectionMedicines for bipolar disorders- Oral > Solid > tablet: 100 mg (scored); 200 mg (scored); 400 mg
IndicationsSectionAntiseizure medicines- Oral > Liquid: 100 mg per 5 mL
- Oral > Solid > tablet: 100 mg (scored); 200 mg (scored); 100 mg (chewable); 200 mg (chewable); 400 mg (scored)
Indications -
Carbetocin Informations générales
SectionUterotonics- Parenteral > General injections > IV: 100 µg per mL (heat stable)
Indications -
Carbimazole Informations générales
SectionThyroid hormones and antithyroid medicinesIndicationsTherapeutic equivalent to methimazole pour Thyrotoxicosis -
Carboplatin Informations générales
SectionCytotoxic medicines- Parenteral > General injections > IV: 50 mg per 5 mL; 150 mg per 15 mL; 450 mg per 45 mL; 600 mg per 60 mL
IndicationsOther specified gliomas of brain Other specified carcinomas of ovary Retinoblastoma Other specified malignant neoplasms of bronchus or lung Malignant neoplasms of nasopharynx Malignant neoplasms of kidney, except renal pelvis Malignant neoplasms of breast Osteosarcoma of bone and articular cartilage of unspecified sites Malignant neoplasms of lip, oral cavity or pharynx Malignant neoplasms of cervix uteri Other specified malignant neoplasms of the ovary Germ cell tumour of testis -
Carmellose Informations générales
SectionOphthalmological preparationsIndicationsTherapeutic equivalent to hypromellose pour Keratoconjunctivitis sicca -
Carvedilol Informations générales
SectionAntianginal medicinesIndicationsTherapeutic equivalent to bisoprolol pour Angina pectorisSectionMedicines used in heart failureIndicationsTherapeutic equivalent to bisoprolol pour Heart failureSectionAntihypertensive medicinesIndicationsTherapeutic equivalent to bisoprolol pour Essential hypertensionSectionAntiarrhythmic medicinesIndicationsTherapeutic equivalent to bisoprolol pour Cardiac arrhythmia -
Caspofungin Informations générales
SectionAntifungal medicinesIndicationsTherapeutic equivalent to micafungin pour Systemic or invasive candidosis -
Cefalexin Informations générales
SectionAccess group antibiotics- Oral > Liquid: 125 mg per 5 mL (anhydrous) powder for oral liquid; 250 mg per 5 mL (anhydrous) powder for oral liquid
- Oral > Solid: 250 mg (as monohydrate)
- Oral > Solid: 250 mg (as monohydrate); 500 mg (as monohydrate)
- Oral > Solid > dispersible tablet: 125 mg; 250 mg
-
Cefazolin Informations générales
SectionAccess group antibiotics- Parenteral > General injections > unspecified: 1 g in vial (as sodium salt) powder for injection
IndicationsPremier choix
Other specified prophylactic measures co-prescrite avec metronidazole Other specified prophylactic measuresAutres indications -
Cefepime Informations générales
SectionWatch group antibiotics- Parenteral > General injections > unspecified: 500 mg in vial (as hydrochloride) powder for injection; 1 g in vial (as hydrochloride) powder for injection; 2 g in vial (as hydrochloride) powder for injection
Indications -
Cefiderocol Informations générales
SectionReserve group antibiotics- Parenteral > General injections > IV: 1 g in vial (as sulfate tosylate) powder for injection
-
Cefixime Informations générales
SectionWatch group antibiotics- Oral > Liquid: 100 mg per 5 mL powder for oral liquid
- Oral > Solid: 200 mg (as trihydrate); 400 mg (as trihydrate)
IndicationsSecond choix
Infectious gastroenteritis or colitis without specification of infectious agent co-prescrite avec azithromycin Gonococcal infection -
Cefotaxime Informations générales
SectionWatch group antibiotics- Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt)
- Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 500 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt); 2 g in vial powder for injection (as sodium salt)
IndicationsPremier choix
Other specified pneumonia (Hospital-acquired pneumonia) Bacterial meningitis Bacterial pneumonia (Community-acquired pneumonia - severe) [children] co-prescrite avec amikacin Inflammatory and other diseases of prostate (severe) co-prescrite avec amikacin Acute pyelonephritis (severe) co-prescrite avec clarithromycin Bacterial pneumonia (Community-acquired pneumonia - severe) co-prescrite avec metronidazole Peritonitis (severe) co-prescrite avec metronidazole Peritonitis (mild-moderate) co-prescrite avec metronidazole Peritoneal abscess (severe) co-prescrite avec metronidazole Peritoneal abscess (mild-moderate)Autres indications -
Ceftaroline Informations générales
SectionReserve group antibiotics- Parenteral > General injections > IV: 400 mg in vial (as fosamil) powder for injection; 600 mg in vial (as fosamil) powder for injection
Indications -
Ceftazidime Informations générales
SectionWatch group antibiotics- Parenteral > General injections > unspecified: 250 mg in vial (as pentahydrate) powder for injection; 1 g in vial (as pentahydrate) powder for injection
-
Ceftazidime + avibactam Informations générales
SectionReserve group antibiotics- Parenteral > General injections > IV: 2 g in vial + 0.5 g in vial powder for injection
-
Ceftolozane + tazobactam Informations générales
SectionReserve group antibiotics- Parenteral > General injections > IV: 1 g + 0.5 g powder for injection
Indications -
Ceftriaxone Informations générales
SectionWatch group antibiotics- Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt)
- Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 500 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt); 2 g in vial powder for injection (as sodium salt)
- Parenteral > Locoregional injections > Intravitreal: 250 mg in vial powder for injection (as sodium salt); 500 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt); 2 g in vial powder for injection (as sodium salt)
- Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 500 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt)
- Parenteral > General injections > unspecified: 2 g in vial; 250 mg in vial powder for injection (as sodium salt); 500 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt)
IndicationsPremier choix
Typhoid fever Bacterial pneumonia (Community-acquired pneumonia - severe) [children] Paratyphoid fever Other specified pneumonia (Hospital-acquired pneumonia) Bacterial meningitis co-prescrite avec amikacin Acute pyelonephritis (severe) co-prescrite avec amikacin Inflammatory and other diseases of prostate (severe) co-prescrite avec azithromycin Gonococcal infection co-prescrite avec clarithromycin Bacterial pneumonia (Community-acquired pneumonia - severe) co-prescrite avec metronidazole Necrotising fasciitis co-prescrite avec metronidazole Peritonitis (mild-moderate) co-prescrite avec metronidazole Peritonitis (severe) co-prescrite avec metronidazole Peritoneal abscess (mild-moderate) co-prescrite avec metronidazole Peritoneal abscess (severe) co-prescrite avec vancomycin EndophthalmitisAutres indications -
Cefuroxime Informations générales
SectionWatch group antibiotics- Parenteral > General injections > IV: 250 mg in vial (as sodium salt) powder for injection; 750 mg in vial (as sodium salt) powder for injection; 1.5 g in vial (as sodium salt) powder for injection
-
Cemiplimab Informations générales
SectionImmunomodulatorsIndicationsTherapeutic equivalent to pembrolizumab pour Other specified malignant neoplasms of bronchus or lung -
Certolizumab pegol Informations générales
SectionImmunomodulators for non-malignant diseaseIndicationsTherapeutic equivalent to adalimumab pour Axial spondyloarthritis Therapeutic equivalent to adalimumab pour Crohn disease site Therapeutic equivalent to adalimumab pour Rheumatoid arthritisSectionMedicines for juvenile joint diseasesIndicationsTherapeutic equivalent to adalimumab pour Juvenile idiopathic arthritis -
Cetirizine Informations générales
SectionAntiallergics and medicines used in anaphylaxisIndicationsTherapeutic equivalent to loratadine pour Allergic or hypersensitivity conditions of unspecified type -
Chlorambucil Informations générales
SectionCytotoxic medicines- Oral > Solid: 2 mg tablet
-
Chloramphenicol Informations générales
SectionAccess group antibiotics- Parenteral > General injections > IV: 1 g in vial powder for injection (sodium succinate)
- Parenteral > General injections > IM: 500 mg in 2 mL ampoule oily suspension for injection
- Oral > Liquid: 150 mg per 5 mL (as palmitate)
- Oral > Solid: 250 mg capsule
-
Chlorhexidine Informations générales
SectionMedicines administered to the neonate [c]- Local > Topical > Solution: 7.1% chlorhexidine digluconate (delivering 4% chlorhexidine)
- Local > Topical > Gel: 7.1% chlorhexidine digluconate (delivering 4% chlorhexidine)
IndicationsSectionAntiseptics- Local > Topical > Solution: 5% (digluconate) for dilution
Indications -
Chlorine base compound Informations générales
SectionDisinfectants- Local > Topical > Powder: 0.1% available chlorine for solution
- Local > Topical > Liquid: 0.1% available chlorine for solution
- Local > Topical > Solid: 0.1% available chlorine for solution
Indications -
Chloroquine Informations générales
SectionAntimalarial medicines > For chemoprevention- Oral > Liquid: 50 mg per 5 mL syrup (as phosphate or sulfate)
- Oral > Solid: 150 mg tablet (as phosphate or sulfate)
SectionAntimalarial medicines > For curative treatment- Parenteral > General injections > IV: 40 mg per mL in 5 mL ampoule (as hydrochloride, phosphate or sulfate)
- Oral > Liquid: 50 mg per 5 mL syrup (as phosphate or sulfate)
- Oral > Solid: 150 mg tablet (as phosphate or sulfate); 100 mg tablet (as phosphate or sulfate)
SectionDisease-modifying anti-rheumatic drugs (DMARDs)- Oral > Solid: 100 mg tablet (as phosphate or sulfate); 150 mg tablet (as phosphate or sulfate)
Indications -
Chlorothiazide Informations générales
SectionAntihypertensive medicinesIndicationsTherapeutic equivalent to hydrochlorothiazide pour Essential hypertensionSectionMedicines used in heart failureIndicationsTherapeutic equivalent to hydrochlorothiazide pour Heart failure -
Chloroxylenol Informations générales
SectionDisinfectants- Local > Topical > Solution: 4.8%
Indications -
Chlorpromazine Informations générales
SectionMedicines for psychotic disorders- Oral > Liquid: 25 mg per 5 mL (hydrochloride)
- Oral > Solid: 100 mg (hydrochloride)
- Oral > Solid: 100 mg (hydrochloride); 10 mg (hydrochloride); 25 mg (hydrochloride); 50 mg (hydrochloride)
- Parenteral > General injections > unspecified: 25 mg per mL in 2 mL ampoule (hydrochloride)
IndicationsTherapeutic equivalent to haloperidol pour Schizophrenia or other primary psychotic disorders Schizophrenia or other primary psychotic disorders -
Chlortalidone Informations générales
SectionAntihypertensive medicinesIndicationsTherapeutic equivalent to hydrochlorothiazide pour Essential hypertensionSectionMedicines used in heart failureIndicationsTherapeutic equivalent to hydrochlorothiazide pour Heart failure -
Chlortetracycline Informations générales
SectionOphthalmological preparations > Anti-infective agentsIndicationsTherapeutic equivalent to tetracycline pour Other specified conjunctivitis Therapeutic equivalent to tetracycline pour Infectious keratitis Therapeutic equivalent to tetracycline pour Infectious blepharitis Therapeutic equivalent to tetracycline pour Trachoma -
Cholera vaccine Informations générales
SectionRecommendations for some high-risk populations- All vaccines should comply with the WHO requirements for biological substances.
Indications -
Ciclesonide Informations générales
SectionAntiasthmatic and medicines for chronic obstructive pulmonary diseaseIndicationsTherapeutic equivalent to budesonide pour Asthma -
Ciclosporin Informations générales
SectionImmunomodulators for non-malignant disease- Parenteral > General injections > IV: 50 mg per mL in 1 mL ampoule concentrate for injection
- Oral > Liquid: 100 mg per mL
- Oral > Solid > capsule: 25 mg
-
Cimetidine Informations générales
SectionAntiulcer medicines- Oral > Solid: 200 mg
- Parenteral > General injections > unspecified: 200 mg in 2 mL ampoule
-
Ciprofloxacin Informations générales
SectionWatch group antibiotics- Parenteral > General injections > IV: 2 mg per mL (as hyclate)
- Oral > Liquid: 250 mg per 5 mL (anhydrous)
- Oral > Solid: 250 mg (as hydrochloride)
- Oral > Solid > dosage form: 250 mg (as hydrochloride); 500 mg (as hydrochloride); 100 mg (as hydrochloride)
- Oral > Solid > dosage form: 250 mg (as hydrochloride); 500 mg (as hydrochloride)
IndicationsPremier choix
Neutropenia (low-risk) Inflammatory and other diseases of prostate (mild to moderate) Typhoid fever Paratyphoid fever Infectious gastroenteritis or colitis without specification of infectious agent Acute pyelonephritis (mild to moderate)Second choix
Cholera Cholera [children] co-prescrite avec metronidazole Peritoneal abscess (mild-moderate) co-prescrite avec metronidazole Peritonitis (mild-moderate)Autres indicationsSectionEar, nose and throat medicines [c]- Local > Otological > drops: 0.3% (as hydrochloride)
Indications -
Cisplatin Informations générales
SectionCytotoxic medicines- Parenteral > General injections > unspecified: 10 mg in vial powder for injection; 50 mg in vial powder for injection
- Parenteral > General injections > IV: 50 mg per 50 mL; 100 mg per 100 mL; 10 mg per 10 mL; 20 mg per 20 mL
IndicationsUnspecified malignant neoplasms of ill-defined or unspecified sites Other specified gliomas of brain Other specified malignant neoplasms of the ovary Other specified malignant neoplasms of bronchus or lung Malignant neoplasms of nasopharynx Germ cell tumour of testis Osteosarcoma of bone and articular cartilage of unspecified sites Malignant neoplasms of lip, oral cavity or pharynx Malignant neoplasms of cervix uteri -
Cladribine Informations générales
SectionMedicines for multiple sclerosis- Oral > Solid > tablet: 10 mg
IndicationsSectionCytotoxic medicines- Parenteral > General injections > IV: 1 mg per mL in 10 mL vial; 2 mg per mL in 5 mL vial
Indications -
Clarithromycin Informations générales
SectionWatch group antibiotics- Oral > Liquid: 125 mg per 5 mL powder for oral liquid; 250 mg per 5 mL powder for oral liquid
- Parenteral > General injections > unspecified: 500 mg in vial powder for injection
- Oral > Solid > dosage form: 500 mg; 250 mg
- Oral > Solid > dosage form: 500 mg
IndicationsPremier choix
co-prescrite avec cefotaxime Bacterial pneumonia (Community-acquired pneumonia - severe) co-prescrite avec ceftriaxone Bacterial pneumonia (Community-acquired pneumonia - severe)Second choix
Acute pharyngitis co-prescrite avec amoxicillin + clavulanic acid Bacterial pneumonia (Community-acquired pneumonia - severe)Autres indications -
Clindamycin Informations générales
SectionAccess group antibiotics- Oral > Liquid: 75 mg per 5 mL (as palmitate hydrochloride)
- Oral > Solid: 150 mg (as hydrochloride) capsule
- Parenteral > General injections > unspecified: 150 mg per mL (as phosphate) injection
- Parenteral > General injections > IV: 150 mg per mL (as phosphate); 600 mg per 4 mL (as phosphate); 900 mg per 6 mL (as phosphate)
- Oral > Liquid: 75 mg per 5 mL powder for oral liquid (as palmitate hydrochloride)
- Oral > Solid: 150 mg (as hydrochloride)
IndicationsPremier choix
co-prescrite avec piperacillin + tazobactam Necrotising fasciitisAutres indications -
Clofazimine Informations générales
SectionAntituberculosis medicines- Oral > Solid: 100 mg; 50 mg
IndicationsSectionAntileprosy medicines- Oral > Solid: 100 mg; 50 mg
Indications -
Clomifene Informations générales
SectionOvulation inducers- Oral > Solid: 50 mg (citrate)
-
Clomipramine Informations générales
SectionMedicines for obsessive compulsive disorders- Oral > Solid: 10 mg (hydrochloride); 25 mg (hydrochloride)
Indications -
Clonazepam Informations générales
SectionAntiseizure medicines- Oral > Solid: 500 µg
Indications -
Clopidogrel Informations générales
SectionAnti-platelet medicines- Oral > Solid: 75 mg; 300 mg
-
Clotrimazole Informations générales
SectionAntifungal medicines- Local > Topical > Other: 1% vaginal cream; 10% vaginal cream; 100 mg vaginal tablet; 500 mg vaginal tablet
Indications -
Cloxacillin Informations générales
SectionAccess group antibiotics- Oral > Liquid: 125 mg per 5 mL (as sodium salt) powder for oral liquid
- Oral > Solid: 500 mg (as sodium salt) capsule; 1 g (as sodium salt) capsule
- Parenteral > General injections > unspecified: 500 mg in vial (as sodium salt) powder for injection
- Oral > Liquid: 125 mg per 5 mL (as sodium salt) powder for oral liquid; 250 mg per 5 mL (as sodium salt) powder for oral liquid
- Parenteral > General injections > unspecified: 500 mg in vial (as sodium salt) powder for injection; 250 mg in vial (as sodium salt) powder for injection
- Oral > Solid > capsule: 500 mg (as sodium salt); 1 g (as sodium salt); 250 mg (as sodium salt)
IndicationsPremier choix
Bacterial infection of joint Osteomyelitis or osteitis Bacterial cellulitis, erysipelas or lymphangitisSecond choix
co-prescrite avec amikacin Sepsis without septic shockAutres indications -
Clozapine Informations générales
SectionMedicines for psychotic disorders- Oral > Solid: 25 mg; 50 mg; 100 mg; 200 mg
-
Coagulation factor IX Informations générales
SectionBlood coagulation factors- Parenteral > General injections > IV: 500 IU in vial powder for injection; 1000 IU in vial powder for injection
-
Coagulation factor IX complex Informations générales
SectionBlood coagulation factorsIndicationsTherapeutic equivalent to coagulation factor IX pour Coagulation defects, purpura or other haemorrhagic or related conditions Therapeutic equivalent to coagulation factor IX pour Haemophilia B -
Coagulation factor VIII Informations générales
SectionBlood coagulation factors- Parenteral > General injections > IV: 250 IU in vial powder for injection; 500 IU in vial powder for injection; 1000 IU in vial powder for injection
Indications -
Coal tar Informations générales
SectionDermatological medicines > Medicines affecting skin differentiation and proliferation- Local > Topical > Solution: 5%
Indications -
Cobicistat + elvitegravir + emtricitabine + tenofovir disoproxil fumarate Informations générales
SectionFixed-dose combinations of antiretrovirals- Oral > Solid: 150 mg + 150 mg + 200 mg + 300 mg (tenofovir disoproxil fumarate equivalent to 245 mg tenofovir disoproxil)
-
Cobicistat + elvitegravir + emtricitabine+ tenofovir alafenamide Informations générales
SectionFixed-dose combinations of antiretrovirals- Oral > Solid: 150 mg + 150 mg + 200 mg + 10 mg
-
Cobimetinib Informations générales
SectionTargeted therapiesIndicationsTherapeutic equivalent to trametinib pour Other specified melanoma of skin -
Codeine Informations générales
-
Colchicine Informations générales
SectionMedicines used to treat gout- Oral > Solid: 0.5 mg
Indications -
Colecalciferol Informations générales
SectionVitamins and minerals- Oral > Liquid: 400 IU per mL
- Oral > Solid: 400 IU; 1000 IU
IndicationsCalcium deficiency Vitamin D deficiency Therapeutic equivalent to ergocalciferol pour Vitamin D deficiency Therapeutic equivalent to ergocalciferol pour Calcium deficiency -
Colistin (injection) Informations générales
SectionReserve group antibiotics- Parenteral > General injections > unspecified: 1 million IU in vial (as colistemethate sodium)
- Parenteral > General injections > unspecified: 1 million IU in vial (as colistemethate sodium) (equivalent to 34 mg colistin base activity)
-
Compound sodium lactate solution Informations générales
SectionSolutions correcting water, electrolyte and acid-base disturbances > Parenteral- Parenteral > General injections > IV: injectable solution
-
Condoms Informations générales
SectionBarrier methods- -
-
Copper-containing intrauterine device Informations générales
SectionIntrauterine devices- -
-
Crizotinib Informations générales
SectionTargeted therapies- Oral > Solid: 200 mg; 250 mg
- Oral > Solid > capsule: 200 mg; 250 mg
-
Cryoprecipitate (not pathogen-reduced) Informations générales
SectionBlood and blood componentsIndicationsTherapeutic equivalent to cryoprecipitate (pathogen-reduced) pour Haemophilia A Therapeutic equivalent to cryoprecipitate (pathogen-reduced) pour Coagulation defects, purpura or other haemorrhagic or related conditions Therapeutic equivalent to cryoprecipitate (pathogen-reduced) pour Von Willebrand disease Therapeutic equivalent to cryoprecipitate (pathogen-reduced) pour Obstetric haemorrhage -
Cryoprecipitate (pathogen-reduced) Informations générales
SectionBlood and blood components- Injection: frozen liquid in bag or lyophilized powder in vial containing:
- > 50 IU Factor VIII
- > 100 IU vWF
- > 140 mg clottable fibrinogen per unit
-
Cyanocobalamin Informations générales
SectionAntianaemia medicines- .
Indications -
Cyclizine Informations générales
SectionMedicines for other common symptoms in palliative care- Oral > Solid: 50 mg tablet
- Parenteral > General injections > unspecified: 50 mg per mL
Indications -
Cyclopentolate Informations générales
SectionDiagnostic agents > Ophthalmic medicinesIndicationsTherapeutic equivalent to tropicamide pour Cycloplegic drugSectionOphthalmological preparations > MydriaticsIndicationsTherapeutic equivalent to atropine pour Anterior uveitis -
Cyclophosphamide Informations générales
SectionCytotoxic medicines- Oral > Solid: 25 mg tablet
- Parenteral > General injections > unspecified: 500 mg in vial powder for injection
- Parenteral > General injections > IV: 500 mg in vial powder for injection; 1 g in vial powder for injection; 2 g in vial powder for injection
- Oral > Solid > dosage form: 25 mg; 50 mg
IndicationsUnspecified malignant neoplasms of ill-defined or unspecified sites Other specified malignant neoplasms of breast Malignant trophoblastic neoplasms of placenta Follicular lymphoma Malignant neoplasms of breast Chronic lymphocytic leukaemia or small lymphocytic lymphoma Rhabdomyosarcoma primary site Hodgkin lymphoma Diffuse large B-cell lymphomas Plasma cell myeloma Other specified gliomas of brain Burkitt lymphoma including Burkitt leukaemia Malignant neoplasms of kidney, except renal pelvis Ewing sarcoma of bone and articular cartilage of unspecified sites Lymphoid leukaemia, not elsewhere classified Anaplastic large cell lymphoma, ALK-negative Anaplastic large cell lymphoma, ALK-positive -
Cycloserine Informations générales
SectionAntituberculosis medicines- Oral > Solid: 250 mg; 125 mg
Indications -
Cytarabine Informations générales
SectionCytotoxic medicines- Parenteral > General injections > unspecified: 100 mg in vial powder for injection
- Parenteral > General injections > unspecified: 100 mg in vial powder for injection; 100 mg per mL in vial
IndicationsUnspecified malignant neoplasms of ill-defined or unspecified sites Lymphoid leukaemia, not elsewhere classified Myeloid leukaemia Acute myeloid leukaemia with recurrent genetic abnormalities Burkitt lymphoma including Burkitt leukaemia Anaplastic large cell lymphoma, ALK-negative Anaplastic large cell lymphoma, ALK-positive Langerhans cell histiocytosis -
Dabigatran Informations générales
SectionMedicines affecting coagulation- Oral > Solid: 110 mg; 150 mg
-
Dabrafenib Informations générales
SectionTargeted therapies- Oral > Solid: 50 mg; 75 mg
Indications -
Dacarbazine Informations générales
SectionCytotoxic medicines- Parenteral > General injections > IV: 100 mg in vial powder for injection; 200 mg in vial powder for injection
Indications -
Daclatasvir Informations générales
SectionMedicines for hepatitis C > Pangenotypic direct-acting antiviral combinations- Oral > Solid > tablet: 30 mg (as hydrochloride); 60 mg (as hydrochloride)
Indications -
Daclatasvir + sofosbuvir Informations générales
SectionMedicines for hepatitis C > Pangenotypic direct-acting antiviral combinations- Oral > Solid > tablet: 60 mg + 400 mg
Indications -
Dactinomycin Informations générales
SectionCytotoxic medicines- Parenteral > General injections > IV: 500 µg in vial powder for injection
-
Dalteparin Informations générales
SectionMedicines affecting coagulationIndicationsTherapeutic equivalent to enoxaparin pour Acute ischaemic heart disease Therapeutic equivalent to enoxaparin pour Venous thromboembolism -
Dapagliflozin Informations générales
SectionOral hypoglycaemic agentsIndicationsTherapeutic equivalent to empagliflozin pour Type 2 diabetes mellitus -
Dapsone Informations générales
SectionAntileprosy medicines- Oral > Solid: 100 mg tablet; 50 mg tablet; 25 mg tablet
Indications -
Daptomycin Informations générales
SectionReserve group antibiotics- Parenteral > General injections > IV: 350 mg in vial powder for injection; 500 mg in vial powder for injection
Indications -
Daratumumab Informations générales
SectionImmunomodulators- Parenteral > General injections > IV: 100 mg per 5 mL; 400 mg per 20 mL
Indications -
Darbepoetin alfa Informations générales
SectionAntianaemia medicinesIndicationsTherapeutic equivalent to erythropoiesis-stimulating agents pour Anaemia due to chronic disease -
Darunavir Informations générales
SectionAntiretrovirals > Protease inhibitors- Oral > Solid: 75 mg; 400 mg; 600 mg; 800 mg
-
Dasabuvir Informations générales
SectionMedicines for hepatitis C > Non-pangenotypic direct-acting antiviral combinations- Oral > Solid: 250 mg tablet
Indications -
Dasatinib Informations générales
SectionTargeted therapies- Oral > Solid: 20 mg tablet; 50 mg tablet; 70 mg tablet; 80 mg tablet; 100 mg tablet; 140 mg tablet
-
Daunorubicin Informations générales
SectionCytotoxic medicines- Parenteral > General injections > IV: 50 mg in vial (as hydrochloride) powder for injection; 20 mg in vial (as hydrochloride) powder for injection; 2 mg per mL in vial (as hydrochloride); 5 mg per mL in vial (as hydrochloride)
-
Deferasirox Informations générales
SectionOther medicines for haemoglobinopathies- Oral > Solid > dispersible tablet: 100 mg; 125 mg; 250 mg; 400 mg; 500 mg
- Oral > Solid > tablet: 90 mg; 180 mg; 360 mg
IndicationsOther specified sickle cell disorders or other haemoglobinopathies Thalassaemias Therapeutic equivalent to deferoxamine pour Thalassaemias -
Deferiprone Informations générales
SectionOther medicines for haemoglobinopathiesIndicationsTherapeutic equivalent to deferasirox pour Other specified sickle cell disorders or other haemoglobinopathies Therapeutic equivalent to deferasirox pour Thalassaemias -
Deferoxamine Informations générales
SectionAntidotes and other substances used in poisonings > Specific- Parenteral > General injections > unspecified: 500 mg in vial powder for injection (mesilate)
SectionOther medicines for haemoglobinopathies- Parenteral > General injections > unspecified: 500 mg in vial powder for injection (mesilate)
-
Delafloxacin Informations générales
SectionWatch group antibiotics- Parenteral > General injections > IV: 300 mg lyophilized powder for injection
- Oral > Solid: 450 mg
Indications -
Delamanid Informations générales
SectionAntituberculosis medicines- Oral > Solid > dispersible tablet: 25 mg
- Oral > Solid > tablet: 50 mg
Indications -
Dengue vaccine Informations générales
SectionRecommendations for some high-risk populations- All vaccines should comply with the WHO requirements for biological substances.
-
Desmopressin Informations générales
SectionMedicines affecting coagulation- Parenteral > General injections > IV: 4 µg per mL in 1 mL ampoule (acetate)
- Local > Nasal > Spray: 10 µg per dose (acetate)
Indications -
Dexamethasone Informations générales
SectionOther medicines administered to the mother- Parenteral > General injections > unspecified: 4 mg per mL (dexamethasone phosphate (as sodium))
SectionHormones and antihormones- Oral > Solid: 4 mg
- Parenteral > General injections > unspecified: 4 mg per mL in 1 mL ampoule (as disodium phosophate salt)
- Oral > Liquid: 2 mg per 5 mL
- Oral > Solid: 2 mg; 4 mg
SectionAntiallergics and medicines used in anaphylaxis- Parenteral > General injections > unspecified: 4 mg per mL in 1 mL ampoule (as disodium phosphate salt)
SectionMedicines for other common symptoms in palliative care- Oral > Liquid: 2 mg per 5 mL
- Oral > Solid: 2 mg; 4 mg
- Parenteral > General injections > unspecified: 4 mg per mL in 1 mL ampoule (as disodium phosphate salt)
IndicationsSectionAntiemetic medicines- Oral > Liquid: 0.5 mg per 5 mL; 2 mg per 5 mL
- Oral > Solid: 0.5 mg; 0.75 mg; 1.5 mg; 4 mg
- Parenteral > General injections > unspecified: 4 mg per mL in 1 mL ampoule (as disodium phosphate salt)
Indications -
Dextran 40 Informations générales
SectionPlasma substitutes- .
Indications -
Dextran 70 Informations générales
SectionPlasma substitutes- Parenteral > General injections > IV: 6% injectable solution
Indications -
Diaphragms Informations générales
SectionBarrier methods- -
-
Diazepam Informations générales
SectionAntiseizure medicines- Local > Rectal > Gel: 5 mg per mL in 0.5 mL rectal delivery system; 5 mg per mL in 2 mL rectal delivery system; 5 mg per mL in 4 mL rectal delivery system
- Local > Rectal > Solution: 2 mg per mL in 1.25 mL rectal tube; 2 mg per mL in 2.5 mL rectal tube; 4 mg per mL in 2.5 mL rectal tube
IndicationsSectionMedicines for other common symptoms in palliative care- Oral > Liquid: 2 mg per 5 mL
- Oral > Solid: 5 mg; 10 mg
- Local > Rectal > Gel: 5 mg per mL in 0.5 mL rectal delivery system; 5 mg per mL in 2 mL rectal delivery system; 5 mg per mL in 4 mL rectal delivery system
- Local > Rectal > Solution: 2 mg per mL in 1.25 mL rectal tube; 2 mg per mL in 2.5 mL rectal tube; 4 mg per mL in 2.5 mL rectal tube
- Parenteral > General injections > unspecified: 5 mg per mL
IndicationsSectionMedicines for anxiety disorders- Oral > Solid: 5 mg (scored); 2 mg (scored)
Indications -
Diazoxide Informations générales
SectionMedicines for hypoglycaemia- Oral > Liquid: 50 mg per mL
- Oral > Solid: 50 mg
-
Didanosine Informations générales
SectionAntiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors- Oral > Liquid: 100 mg buffered powder for oral solution; 167 mg buffered powder for oral solution; 250 mg buffered powder for oral solution
- Oral > Solid: 25 mg buffered chewable dispersible tablet; 50 mg buffered chewable dispersible tablet; 100 mg buffered chewable dispersible tablet; 150 mg buffered chewable dispersible tablet; 200 mg buffered chewable dispersible tablet; 125 mg unbuffered enteric coated capsule; 200 mg unbuffered enteric coated capsule; 250 mg unbuffered enteric coated capsule; 400 mg unbuffered enteric coated capsule
-
Diethylcarbamazine Informations générales
SectionAntifilarials- Oral > Solid: 50 mg tablet (dihydrogen citrate); 100 mg tablet (dihydrogen citrate)
Indications -
Digitoxin Informations générales
SectionMedicines used in heart failure- Parenteral > General injections > IV: 0.2 mg in 1 mL ampoule
- Oral > Solid: 50 µg; 100 µg
Indications -
Digoxin Informations générales
SectionAntiarrhythmic medicines- Parenteral > General injections > IV: 250 µg per mL in 2 mL ampoule
- Oral > Liquid: 50 µg per mL
- Oral > Solid: 62.5 µg; 250 µg
IndicationsSectionMedicines used in heart failure- Parenteral > General injections > IV: 250 µg per mL in 2 mL ampoule; 100 µg per mL in 1 mL ampoule
- Oral > Liquid: 50 µg per mL
- Oral > Solid > tablet: 62.5 µg; 250 µg; 125 µg
Indications -
Dihydroartemisinin + piperaquine phosphate Informations générales
SectionAntimalarial medicines > For curative treatment- Oral > Solid: 40 mg + 320 mg tablet; 20 mg + 160 mg tablet
-
Dihydroergocryptine mesylate Informations générales
SectionAntiseizure medicines- Oral > Solid:
Indications -
Diloxanide Informations générales
SectionAntiamoebic and antigiardiasis medicines- Oral > Solid: 500 mg (furoate)
Indications -
Dimercaprol Informations générales
SectionAntidotes and other substances used in poisonings > Specific- Parenteral > General injections > IM: 50 mg per mL in 2 mL ampoule
-
Diphtheria antitoxin Informations générales
SectionImmunologicals > Sera, immunoglobulins and monoclonal antibodies- Parenteral > General injections > IM: 10000 IU in vial; 20000 IU in vial
Indications -
Diphtheria vaccine Informations générales
SectionRecommendations for all immunization programmes- All vaccines should comply with the WHO requirements for biological substances.
Indications -
Diphtheria-pertussis-tetanus vaccine Informations générales
SectionRecommendations for all immunization programmes- All vaccines should comply with the WHO requirements for biological substances.
-
Diphtheria-tetanus vaccine Informations générales
SectionRecommendations for all immunization programmes- All vaccines should comply with the WHO requirements for biological substances.
-
Docetaxel Informations générales
SectionCytotoxic medicines- Parenteral > General injections > IV: 20 mg per mL; 40 mg per mL
-
Docusate sodium Informations générales
SectionMedicines for other common symptoms in palliative care- Oral > Liquid: 50 mg per 5 mL oral liquid
- Oral > Solid: 100 mg capsule
Indications -
Dolasetron Informations générales
SectionMedicines for other common symptoms in palliative careIndicationsTherapeutic equivalent to ondansetron pour Palliative careSectionAntiemetic medicinesIndicationsTherapeutic equivalent to ondansetron pour Nausea or vomiting -
Dolutegravir Informations générales
SectionAntiretrovirals > Integrase inhibitors- Oral > Solid: 50 mg tablet; 10 mg tablet (dispersible, scored)
-
Dolutegravir + lamivudine + tenofovir Informations générales
SectionFixed-dose combinations of antiretrovirals- Oral > Solid: 50 mg + 300 mg + 300 mg (tenofovir disoproxil fumarate equivalent to 245 mg tenofovir disoproxil)
-
Donepezil Informations générales
SectionMedicines for diseases of the nervous system- Oral > Liquid: 1 mg per mL (hydrochloride)
- Oral > Solid > tablet: 5 mg (hydrochloride); 10 mg (hydrochloride); 5 mg (hydrochloride) (orodispersible); 10 mg (hydrochloride) (orodispersible)
Indications -
Dopamine Informations générales
SectionMedicines used in heart failure- Parenteral > General injections > IV: 40 mg per mL in 5 mL vial (hydrochloride)
Indications -
Doxorubicin Informations générales
SectionCytotoxic medicines- Parenteral > General injections > IV: 10 mg in vial (hydrochloride); 50 mg in vial (hydrochloride)
- Parenteral > General injections > IV: 10 mg in vial (hydrochloride) powder for injection; 50 mg in vial (hydrochloride) powder for injection; 2 mg per mL in 5 mL vial (hydrochloride); 2 mg per mL in 25 mL vial (hydrochloride)
IndicationsUnspecified malignant neoplasms of ill-defined or unspecified sites Rhabdomyosarcoma primary site Malignant neoplasms of breast Hodgkin lymphoma Diffuse large B-cell lymphomas Plasma cell myeloma Follicular lymphoma Burkitt lymphoma including Burkitt leukaemia Malignant neoplasms of kidney, except renal pelvis Osteosarcoma of bone and articular cartilage of unspecified sites Lymphoid leukaemia, not elsewhere classified Anaplastic large cell lymphoma, ALK-negative Other specified malignant neoplasms of breast Anaplastic large cell lymphoma, ALK-positive Ewing sarcoma of bone and articular cartilage of unspecified sites Kaposi sarcoma of unspecified primary site -
Doxorubicin (as pegylated liposomal) Informations générales
SectionCytotoxic medicines- Parenteral > General injections > IV: 2 mg per mL in 10 mL vial (hydrochloride); 2 mg per mL in 25 mL vial (hydrochloride)
Indications -
Doxycycline Informations générales
SectionAccess group antibiotics- Oral > Liquid: 25 mg per 5 mL (anhydrous); 50 mg per 5 mL (anhydrous)
- Oral > Solid: 100 mg (as hyclate); 50 mg (as hyclate)
- Parenteral > General injections > unspecified: 100 mg in vial powder for injection
- Oral > Liquid: 25 mg per 5 mL powder for oral liquid (monohydrate); 50 mg per 5 mL (calcium)
- Oral > Solid > dispersible tablet: 100 mg (as monohydrate)
- Oral > Solid > dosage form: 50 mg (as hyclate); 100 mg (as hyclate)
- Oral > Solid > dosage form: 100 mg (as hyclate)
IndicationsAutres indicationsSectionAntimalarial medicines > For curative treatment- Oral > Solid: 100 mg (hydrochloride or hyclate); 100 mg dispersible tablet (as monohydrate)
IndicationsSectionAntimalarial medicines > For chemoprevention- Oral > Solid: 100 mg (hydrochloride or hyclate)
Indications -
Durvalumab Informations générales
SectionImmunomodulators- Parenteral > General injections > IV: 120 mg per 2.4 mL in vial; 500 mg per 10 mL in vial
-
Edoxaban Informations générales
SectionMedicines affecting coagulationIndicationsTherapeutic equivalent to dabigatran pour Venous thromboembolism Therapeutic equivalent to dabigatran pour Other specified atrial fibrillation -
Efavirenz Informations générales
SectionAntiretrovirals > Non-nucleoside reverse transcriptase inhibitors- Oral > Solid: 600 mg tablet
-
Efavirenz + emtricitabine + tenofovir Informations générales
SectionFixed-dose combinations of antiretrovirals- Oral > Solid: 600 mg + 200 mg + 300 mg (tenofovir disoproxil fumarate equivalent to 245 mg tenofovir disoproxil)
-
Efavirenz + lamivudine + tenofovir Informations générales
SectionFixed-dose combinations of antiretrovirals- Oral > Solid: 400 mg + 300 mg + 300 mg (tenofovir disoproxil fumarate, equivalent to 245 mg tenofovir disoproxil)
IndicationsHuman immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified Therapeutic equivalent to efavirenz + emtricitabine + tenofovir pour Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified -
Eflornithine Informations générales
SectionMedicines for the treatment of 2nd stage African trypanosomiasis- Parenteral > General injections > IV: 200 mg per mL in 50 mL bottle (hydrochloride)
Indications -
Elbasvir + grazoprevir Informations générales
SectionMedicines for hepatitis C > Non-pangenotypic direct-acting antiviral combinations- Oral > Solid: 50 mg + 100 mg
Indications -
Empagliflozin Informations générales
SectionOral hypoglycaemic agents- Oral > Solid: 10 mg; 25 mg
Indications -
Emtricitabine Informations générales
SectionAntiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors- Oral > Liquid: 10 mg per mL
- Oral > Solid: 200 mg
-
Emtricitabine + rilpivirine + tenofovir alafenamide Informations générales
SectionFixed-dose combinations of antiretrovirals- Oral > Solid: 200 mg + 25 mg + 25 mg
-
Emtricitabine + rilpivirine + tenofovir disoproxil fumarate Informations générales
SectionFixed-dose combinations of antiretrovirals- Oral > Solid: 200 mg + 25 mg + 300 mg (tenofovir disoproxil fumarate equivalent to 245 mg tenofovir disoproxil)
-
Emtricitabine + tenofovir Informations générales
SectionFixed-dose combinations of antiretrovirals- Oral > Solid: 200 mg + 300 mg (tenofovir disoproxil fumarate equivalent to 245 mg tenofovir disoproxil)
-
Emtricitabine + tenofovir alafenamide Informations générales
SectionFixed-dose combinations of antiretrovirals- Oral > Solid: 200 mg + 10 mg; 200 mg + 25 mg
-
Enalapril Informations générales
SectionAntihypertensive medicines- Oral > Liquid: 1 mg per mL (as hydrogen maleate)
- Oral > Solid > tablet: 2.5 mg (as hydrogen maleate); 5 mg (as hydrogen maleate); 10 mg (as hydrogen maleate)
IndicationsSectionMedicines used in heart failure- Oral > Solid > tablet: 2.5 mg (as hydrogen maleate); 5 mg (as hydrogen maleate); 10 mg (as hydrogen maleate)
Indications -
Encorafenib Informations générales
SectionTargeted therapiesIndicationsTherapeutic equivalent to dabrafenib pour Other specified melanoma of skin -
Enoxaparin Informations générales
SectionMedicines affecting coagulation- Parenteral > General injections > SC: 20 mg per 0.2 mL in prefilled syringe; 40 mg per 0.4 mL in prefilled syringe; 60 mg per 0.6 mL in prefilled syringe; 80 mg per 0.8 mL in prefilled syringe; 100 mg per 1 mL in prefilled syringe; 120 mg per 0.8 mL in prefilled syringe; 150 mg per 1 mL in prefilled syringe; 150 mg per 1 mL in ampoule; 20 mg per 0.2 mL in ampoule; 40 mg per 0.4 mL in ampoule; 60 mg per 0.6 mL in ampoule; 80 mg per 0.8 mL in ampoule; 100 mg per 1 mL in ampoule; 120 mg per 0.8 mL in ampoule
Indications -
Entecavir Informations générales
SectionMedicines for hepatitis B > Nucleoside/Nucleotide reverse transcriptase inhibitors- Oral > Liquid: 0.05 mg per mL
- Oral > Solid: 0.5 mg; 1 mg
Indications -
Enzalutamide Informations générales
SectionHormones and antihormones- Oral > Solid: 40 mg
IndicationsTherapeutic equivalent to abiraterone pour Malignant neoplasms of prostate Malignant neoplasms of prostate -
Ephedrine Informations générales
SectionLocal anaesthetics- Parenteral > Locoregional injections > Spinal anaesthesia: 30 mg per mL in 1 mL ampoule (ephedrine hydrochloride)
-
Epinephrine Informations générales
SectionAntiarrhythmic medicines- Parenteral > General injections > IV: 100 µg per mL in 10 mL ampoule (as acid tartrate or hydrochloride)
IndicationsSectionOphthalmological preparations > Mydriatics- Local > Ophthalmological > Solution (eye drops): 2% (as hydrochloride)
IndicationsSectionAntiasthmatic and medicines for chronic obstructive pulmonary disease- Parenteral > General injections > unspecified: 1 mg per mL in ampoule (as hydrochloride or hydrogen tartrate)
IndicationsSectionAntiallergics and medicines used in anaphylaxis- Parenteral > General injections > unspecified: 1 mg in 1 mL ampoule (as hydrochloride or hydrogen tartrate)
Indications -
Epoetin alfa Informations générales
SectionAntianaemia medicinesIndicationsTherapeutic equivalent to erythropoiesis-stimulating agents pour Anaemia due to chronic disease -
Epoetin beta Informations générales
SectionAntianaemia medicinesIndicationsTherapeutic equivalent to erythropoiesis-stimulating agents pour Anaemia due to chronic disease -
Epoetin theta Informations générales
SectionAntianaemia medicinesIndicationsTherapeutic equivalent to erythropoiesis-stimulating agents pour Anaemia due to chronic disease -
Equine rabies immunoglobulin Informations générales
SectionImmunologicals > Sera, immunoglobulins and monoclonal antibodies- Parenteral > Locoregional injections > Intradermal: 150 IU per mL in vial; 200 IU per mL in vial; 300 IU per mL in vial; 400 IU per mL in vial
Indications -
Eravacycline Informations générales
SectionReserve group antibiotics- Parenteral > General injections > IV: 50 mg lyophilized powder for injection
Indications -
Ergocalciferol Informations générales
SectionVitamins and minerals- Oral > Liquid: 250 µg per mL (10 000 IU per mL)
- Oral > Solid: 1.25 mg (50 000 IU)
IndicationsTherapeutic equivalent to colecalciferol pour Calcium deficiency Therapeutic equivalent to colecalciferol pour Vitamin D deficiency Vitamin D deficiency Calcium deficiency -
Ergometrine Informations générales
SectionUterotonics- Parenteral > General injections > unspecified: 200 µg in 1 mL ampoule (hydrogen maleate)
Indications -
Erlotinib Informations générales
SectionTargeted therapies- Oral > Solid: 100 mg; 150 mg
-
Erythromycin Informations générales
SectionWatch group antibiotics- Parenteral > General injections > IV: 500 mg in vial powder for injection (as lactobionate)
- Oral > Liquid: 125 mg per 5 mL (as stearate or ethylsuccinate)
- Oral > Solid: 250 mg (as stearate or ethylsuccinate)
IndicationsSecond choix
Therapeutic equivalent to clarithromycin pour Acute pharyngitisAutres indicationsSectionOphthalmological preparations > Anti-infective agents- Local > Ophthalmological > Ointment: 0.5%
Indications -
Erythropoiesis-stimulating agents Informations générales
SectionAntianaemia medicines- Parenteral > General injections > unspecified: 1000 IU per 0.5 mL pre-filled syringe; 2000 IU per 0.5 mL pre-filled syringe; 3000 IU per 0.3 mL pre-filled syringe; 4000 IU per 0.4 mL pre-filled syringe; 5000 IU per 0.5 mL pre-filled syringe; 6000 IU per 0.6 mL pre-filled syringe; 8000 IU per 0.8 mL pre-filled syringe; 10000 IU per 1 mL pre-filled syringe; 20000 IU per 0.5 mL pre-filled syringe; 40000 IU per 1 mL pre-filled syringe
Indications -
Estradiol Informations générales
SectionEstrogens- Oral > Solid > tablet: 0.5 mg; 1 mg; 2 mg
Indications -
Estradiol cypionate + medroxyprogesterone acetate Informations générales
SectionInjectable hormonal contraceptives- Parenteral > General injections > IM: 5 mg + 25 mg
-
Etanercept Informations générales
SectionImmunomodulators for non-malignant diseaseIndicationsTherapeutic equivalent to adalimumab pour Axial spondyloarthritis Therapeutic equivalent to adalimumab pour Crohn disease site Therapeutic equivalent to adalimumab pour Rheumatoid arthritisSectionMedicines for juvenile joint diseasesIndicationsTherapeutic equivalent to adalimumab pour Juvenile idiopathic arthritis -
Ethambutol Informations générales
SectionAntituberculosis medicines- Parenteral > General injections > IV: 1000 mg per 10 mL; 2000 mg per 20 mL
- Oral > Solid > dispersible tablet: 100 mg
- Oral > Solid > tablet: 100 mg (hydrochloride); 400 mg (hydrochloride)
Indications -
Ethambutol + isoniazid Informations générales
SectionAntituberculosis medicines- Oral > Solid: 400 mg + 150 mg tablet
Indications -
Ethambutol + isoniazid + pyrazinamide + rifampicin Informations générales
SectionAntituberculosis medicines- Oral > Solid: 275 mg + 75 mg + 400 mg + 150 mg tablet
Indications -
Ethambutol + isoniazid + rifampicin Informations générales
SectionAntituberculosis medicines- Oral > Solid: 275 mg + 75 mg + 150 mg tablet
Indications -
Ethanol Informations générales
SectionAntiseptics- Local > Topical > Solution: 70% (denatured)
Indications -
Ether Informations générales
SectionGeneral anaesthetics and oxygen > Inhalational medicines- Respiratory > Inhalation > solution:
Indications -
Ethinylestradiol + etonogestrel Informations générales
SectionIntravaginal contraceptives- Local > Vaginal > vaginal ring: 2.7 mg + 11.7 mg
-
Ethinylestradiol + levonorgestrel Informations générales
SectionOral hormonal contraceptives- Oral > Solid: 50 µg + 250 µg [4]
- Oral > Solid: 30 µg + 150 µg
-
Ethinylestradiol + norethisterone Informations générales
SectionOral hormonal contraceptives- Oral > Solid: 35 µg + 1 mg
-
Ethionamide Informations générales
SectionAntituberculosis medicines- Oral > Solid > dispersible tablet: 125 mg
- Oral > Solid > tablet: 250 mg
-
Ethosuximide Informations générales
SectionAntiseizure medicines- Oral > Liquid: 250 mg per 5 mL
- Oral > Solid: 250 mg
Indications -
Etonogestrel-releasing implant Informations générales
SectionImplantable contraceptives- Implant > Subdermal: 68 mg single rod
-
Etoposide Informations générales
SectionCytotoxic medicines- Parenteral > General injections > IV: 20 mg per mL in 5 mL ampoule
- Oral > Solid: 100 mg capsule
- Parenteral > General injections > IV: 20 mg per mL in 5 mL ampoule; 100 mg in vial powder for injection (as phosphate)
- Oral > Solid: 100 mg capsule; 50 mg capsule
IndicationsUnspecified malignant neoplasms of ill-defined or unspecified sites Burkitt lymphoma including Burkitt leukaemia Ewing sarcoma of bone and articular cartilage of unspecified sites Lymphoid leukaemia, not elsewhere classified Myeloid leukaemia Other specified malignant neoplasms of the ovary Other specified malignant neoplasms of bronchus or lung Germ cell tumour of testis Malignant trophoblastic neoplasms of placenta Malignant neoplasms of kidney, except renal pelvis Osteosarcoma of bone and articular cartilage of unspecified sites Hodgkin lymphoma Retinoblastoma Anaplastic large cell lymphoma, ALK-positive Anaplastic large cell lymphoma, ALK-negative -
Everolimus Informations générales
SectionTargeted therapies- Oral > Solid > dispersible tablet: 2 mg; 3 mg; 5 mg
- Oral > Solid > tablet: 2.5 mg; 5 mg; 7.5 mg; 10 mg
Indications -
Fentanyl Informations générales
SectionOpioid analgesics- Local > Topical > Transdermal patch: 12 µg/hour; 25 µg/hour; 50 µg/hour; 75 µg/hour; 100 µg/hour
- Oral > Solid: 100 to 800 µg sub-lingual tablet (as citrate); 200 to 1600 µg lozenge (as citrate)
- Oral > Other: 200 to 1200 µg buccal film (as citrate)
-
Ferrous salt Informations générales
SectionAntianaemia medicines- Oral > Liquid: 25 mg per mL iron (as sulfate)
- Oral > Solid: 60 mg iron
Indications -
Ferrous salt + folic acid Informations générales
SectionAntianaemia medicines- Oral > Solid: 60 mg iron + 2.8 mg
- Oral > Solid > tablet: 60 mg elemental iron + 400 µg tablet; 60 mg elemental iron + 2.8 mg
-
Fexinidazole Informations générales
SectionMedicines for the treatment of 1st stage African trypanosomiasis- Oral > Solid: 600 mg
IndicationsSectionMedicines for the treatment of 2nd stage African trypanosomiasis- Oral > Solid: 600 mg
Indications -
Fexofenadine Informations générales
SectionAntiallergics and medicines used in anaphylaxisIndicationsTherapeutic equivalent to loratadine pour Allergic or hypersensitivity conditions of unspecified type -
Fifth generation cephalosporins Informations générales
SectionReserve group antibiotics- .
Indications -
Filgrastim Informations générales
SectionImmunomodulators- Parenteral > General injections > SC: 120 µg per 0.2 mL in prefilled syringe; 300 µg per 0.5 mL in prefilled syringe; 480 µg per 0.8 mL in prefilled syringe; 300 µg per mL in 1 mL vial; 480 µg per 1.6 mL in 1.6 mL vial
Indications -
Fingolimod Informations générales
SectionImmunomodulators for non-malignant disease- Oral > Solid: 0.25 mg; 0.5 mg
Indications -
Flomoxef Informations générales
SectionWatch group antibiotics- Parenteral > General injections > IV: 0.5 g in vial powder for injection; 1 g in vial powder for injection
-
Fluconazole Informations générales
SectionAntifungal medicines- Parenteral > General injections > IV: 2 mg per mL in vial
- Oral > Liquid: 50 mg per 5 mL; 50 mg per 5 mL powder for oral liquid
- Oral > Solid > capsule: 50 mg
Indications -
Flucytosine Informations générales
SectionAntifungal medicines- Parenteral > General injections > IV: 2.5 g per 250 mL infusion
- Oral > Solid: 250 mg capsule
Indications -
Fludarabine Informations générales
SectionCytotoxic medicines- Parenteral > General injections > IV: 50 mg in vial (fludarabine phosphate) powder for injection
- Oral > Solid: 10 mg tablet (fludarabine phosphate)
-
Fludrocortisone Informations générales
SectionAdrenal hormones and synthetic substitutes- Oral > Solid: 100 µg (acetate)
Indications -
Flunisolide Informations générales
SectionAntiasthmatic and medicines for chronic obstructive pulmonary diseaseIndicationsTherapeutic equivalent to budesonide pour Asthma -
Fluorescein Informations générales
SectionDiagnostic agents > Ophthalmic medicines- Local > Ophthalmological > Solution (eye drops): 1% (sodium salt)
Indications -
Fluoride Informations générales
SectionDental medicines and preparations- Local > Dental > Gel: 2500 to 12500 ppm fluoride (any type)
- Local > Dental > Toothpaste, cream or gel: 1000 to 1500 ppm fluoride (any type)
- Local > Dental > Mouthrinse: 230 to 900 ppm fluoride (any type)
- Local > Dental > Varnish: 22500 ppm fluoride (any type)
Indications -
Fluorouracil Informations générales
SectionDermatological medicines > Medicines affecting skin differentiation and proliferation- Local > Topical > Ointment: 5%
IndicationsSectionCytotoxic medicines- Parenteral > General injections > IV: 50 mg per mL in 5 mL ampoule
- Parenteral > General injections > IV: 50 mg per mL in vial
-
Fluoxetine Informations générales
SectionMedicines for depressive disorders- Oral > Solid: 20 mg (as hydrochloride)
IndicationsSectionMedicines for other common symptoms in palliative care- Oral > Solid: 20 mg (as hydrochloride)
IndicationsSectionMedicines for anxiety disorders- Oral > Solid: 20 mg (as hydrochloride)
SectionMedicines for obsessive compulsive disorders- Oral > Solid: 20 mg (as hydrochloride)
Indications -
Fluphenazine Informations générales
SectionMedicines for psychotic disorders- Parenteral > General injections > IM: 25 mg per mL in ampoule (decanoate); 25 mg per mL in ampoule (enanthate)
-
Flutamide Informations générales
SectionHormones and antihormonesIndicationsTherapeutic equivalent to bicalutamide pour Malignant neoplasms of prostate -
Fluticasone Informations générales
SectionAntiasthmatic and medicines for chronic obstructive pulmonary diseaseIndicationsTherapeutic equivalent to budesonide pour Asthma -
Fluticasone + formoterol Informations générales
SectionAntiasthmatic and medicines for chronic obstructive pulmonary diseaseIndicationsTherapeutic equivalent to budesonide + formoterol pour Asthma -
Fluticasone furoate + vilanterol Informations générales
SectionAntiasthmatic and medicines for chronic obstructive pulmonary diseaseIndicationsTherapeutic equivalent to budesonide + formoterol pour Asthma -
Fluvastatin Informations générales
SectionLipid-lowering agentsIndicationsTherapeutic equivalent to simvastatin pour Mixed hyperlipidaemia Therapeutic equivalent to simvastatin pour Coronary atherosclerosis -
Folic acid Informations générales
SectionAntianaemia medicines- Oral > Solid: 1 mg tablet; 5 mg tablet
- Oral > Solid: 400 µg
-
Fomepizole Informations générales
SectionAntidotes and other substances used in poisonings > Specific- Parenteral > General injections > IV: 5 mg per mL in 20 mL ampoule (sulfate); 1 g per mL in 1.5 mL ampoule (base)
-
Fosfomycin (injection) Informations générales
SectionReserve group antibiotics- Parenteral > General injections > IV: 2 g in vial (as sodium) powder for injection; 4 g in vial (as sodium) powder for injection
-
Fourth generation cephalosporins Informations générales
SectionWatch group antibiotics- .
Indications -
Fresh-frozen plasma Informations générales
SectionBlood and blood components- Parenteral > General injections > IV:
Indications -
Fulvestrant Informations générales
SectionHormones and antihormones- Parenteral > General injections > IV: 250 mg per 5 mL
Indications -
Furosemide Informations générales
SectionMedicines used in heart failure- Parenteral > General injections > IV: 10 mg per mL in 2 mL ampoule; 10 mg per mL in 5 mL ampoule
- Oral > Liquid: 20 mg per 5 mL; 50 mg per 5 mL
- Oral > Solid > tablet: 40 mg; 20 mg
IndicationsSectionDiuretics- Parenteral > General injections > IV: 10 mg per mL in 2 mL ampoule; 10 mg per mL in 5 mL ampoule
- Oral > Liquid: 20 mg per 5 mL; 50 mg per 5 mL
- Oral > Solid > tablet: 40 mg; 20 mg
Indications -
Gabapentin Informations générales
SectionNon-opioids and non-steroidal anti-inflammatory medicines (NSAIMs)- Oral > Solid: 100 mg; 200 mg; 300 mg; 400 mg; 600 mg; 800 mg
Indications -
Gallamine Informations générales
SectionMuscle relaxants (peripherally-acting) and cholinesterase inhibitors- Parenteral > General injections > IV: 40 mg per mL in 2 mL ampoule (gallamine triethiodide)
Indications -
Gatifloxacin Informations générales
SectionAntituberculosis medicines- Oral > Solid: 200 mg; 400 mg
Indications -
Gefitinib Informations générales
SectionTargeted therapiesIndicationsTherapeutic equivalent to erlotinib pour Other specified malignant neoplasms of bronchus or lung -
Gemcitabine Informations générales
SectionCytotoxic medicines- Parenteral > General injections > IV: 200 mg in vial powder for injection; 1 g in vial powder for injection
-
Gentamicin Informations générales
SectionAccess group antibiotics- Parenteral > General injections > unspecified: 10 mg per mL in 2 mL vial (as sulfate); 40 mg per mL in 2 mL vial (as sulfate)
IndicationsPremier choix
Neonatal meningitis co-prescrite avec amoxicillin Sepsis without septic shock co-prescrite avec amoxicillin Bacterial pneumonia (Community-acquired pneumonia - severe) [children] co-prescrite avec ampicillin Bacterial pneumonia (Community-acquired pneumonia - severe) [children] co-prescrite avec ampicillin Sepsis without septic shock co-prescrite avec ampicillin Acute malnutrition in infants, children or adolescents (complicated) [children] co-prescrite avec ampicillin Peritoneal abscess (severe) co-prescrite avec ampicillin Peritonitis (mild-moderate) co-prescrite avec ampicillin Peritonitis (severe) co-prescrite avec ampicillin Peritoneal abscess (mild-moderate) co-prescrite avec benzylpenicillin Bacterial pneumonia (Community-acquired pneumonia - severe) [children] co-prescrite avec benzylpenicillin Acute malnutrition in infants, children or adolescents (complicated) [children] co-prescrite avec benzylpenicillin Sepsis without septic shockAutres indicationsSectionOphthalmological preparations > Anti-infective agents- Local > Ophthalmological > Solution (eye drops): 0.3% (gentamicin sulfate)
Indications -
Glass ionomer cement Informations générales
SectionDental medicines and preparations- Local > Dental > Powder + liquid: Single-use capsules: 0.4 g powder + 0.09 mL liquid; Multi-use bottle: powder + liquid
Indications -
Glatiramer acetate Informations générales
SectionMedicines for multiple sclerosis- Parenteral > General injections > SC: 20 mg per mL; 40 mg per mL
- Parenteral > General injections > SC: 20 mg per mL in pre-filled syringe; 40 mg per mL in pre-filled syringe
-
Glecaprevir + pibrentasvir Informations générales
SectionMedicines for hepatitis C > Pangenotypic direct-acting antiviral combinations- Oral > Solid: 50 mg + 20 mg granules
- Oral > Solid > tablet: 100 mg + 40 mg
Indications -
Glibenclamide Informations générales
SectionOral hypoglycaemic agents- Oral > Solid: 5 mg; 2.5 mg
Indications -
Gliclazide Informations générales
SectionOral hypoglycaemic agents- Oral > Solid: 30 mg controlled-release; 60 mg controlled-release; 80 mg controlled-release
Indications -
Glucagon Informations générales
SectionMedicines for hypoglycaemia- Parenteral > General injections > unspecified: 1 mg per mL
Indications -
Glucose Informations générales
SectionSolutions correcting water, electrolyte and acid-base disturbances > Parenteral- Parenteral > General injections > IV: 5% isotonic; 10% hypertonic
- Parenteral > General injections > IV: 50% hypertonic
-
Glucose + sodium chloride Informations générales
SectionSolutions correcting water, electrolyte and acid-base disturbances > Parenteral- Parenteral > General injections > IV: 4% + 0.18% (equivalent to Na+ 30 mmol/L and Cl- 30 mmol/L; 5% + 0.9% (equivalent to Na+ 150 mmol/L and Cl- 150 mmol/L); 5% + 0.45% (equivalent to Na+ 75 mmol/L and Cl- 75 mmol/L)
-
Glutaral Informations générales
SectionDisinfectants- Local > Topical > Solution: 2%
Indications -
Glyceryl trinitrate Informations générales
SectionAntianginal medicines- Oral > Solid: 500 µg sublingual tablet
Indications -
Glycopyrronium Informations générales
SectionAntiasthmatic and medicines for chronic obstructive pulmonary diseaseIndicationsTherapeutic equivalent to tiotropium bromide pour Chronic obstructive pulmonary disease -
Golimumab Informations générales
SectionImmunomodulators for non-malignant diseaseIndicationsTherapeutic equivalent to adalimumab pour Axial spondyloarthritis Therapeutic equivalent to adalimumab pour Crohn disease site Therapeutic equivalent to adalimumab pour Rheumatoid arthritisSectionMedicines for juvenile joint diseasesIndicationsTherapeutic equivalent to adalimumab pour Juvenile idiopathic arthritis -
Goserelin Informations générales
SectionHormones and antihormonesIndicationsTherapeutic equivalent to leuprorelin pour Malignant neoplasms of breast Therapeutic equivalent to leuprorelin pour Malignant neoplasms of prostate -
Granisetron Informations générales
SectionMedicines for other common symptoms in palliative careIndicationsTherapeutic equivalent to ondansetron pour Palliative careSectionAntiemetic medicinesIndicationsTherapeutic equivalent to ondansetron pour Nausea or vomiting -
Griseofulvin Informations générales
SectionAntifungal medicines- Oral > Liquid: 125 mg per 5 mL
- Oral > Solid: 125 mg; 250 mg
Indications -
Haemophilus influenzae type b vaccine Informations générales
SectionRecommendations for all immunization programmes- All vaccines should comply with the WHO requirements for biological substances.
-
Haloperidol Informations générales
SectionMedicines for other common symptoms in palliative care- Oral > Liquid: 2 mg per mL
- Oral > Solid: 0.5 mg; 2 mg; 5 mg
- Parenteral > General injections > unspecified: 5 mg per mL in 1-mL ampoule
IndicationsSectionMedicines for psychotic disorders- Parenteral > General injections > IM: 5 mg per mL in ampoule
- Oral > Solid: 2 mg; 5 mg
-
Haloperidol decanoate Informations générales
SectionMedicines for psychotic disordersIndicationsTherapeutic equivalent to fluphenazine pour Schizophrenia or other primary psychotic disorders -
Halothane Informations générales
SectionGeneral anaesthetics and oxygen > Inhalational medicines- Respiratory > Inhalation > liquid:
Indications -
Heparin sodium Informations générales
SectionMedicines affecting coagulation- Parenteral > General injections > IV: 1000 IU per mL in 1 mL ampoule; 20000 IU per mL in 1 mL ampoule; 5000 IU per mL in 1 mL ampoule
-
Hepatitis A vaccine Informations générales
SectionRecommendations for some high-risk populations- All vaccines should comply with the WHO requirements for biological substances.
Indications -
Hepatitis B vaccine Informations générales
SectionRecommendations for all immunization programmes- All vaccines should comply with the WHO requirements for biological substances.
Indications -
Homatropine Informations générales
SectionOphthalmological preparations > Mydriatics- Local > Ophthalmological > Solution (eye drops): 2% (hydrobromide)
Indications -
Human papilloma virus (HPV) vaccine Informations générales
SectionRecommendations for all immunization programmes- All vaccines should comply with the WHO requirements for biological substances.
-
Hydralazine Informations générales
SectionAntihypertensive medicines- Parenteral > General injections > IV: 20 mg in ampoule powder for injection (hydrochloride)
- Oral > Solid: 50 mg tablet; 25 mg tablet (hydrochloride)
- Oral > Solid: 50 mg (hydrochloride); 25 mg (hydrochloride)
Indications -
Hydrochlorothiazide Informations générales
SectionAntihypertensive medicines- Oral > Liquid: 50 mg per 5 mL
- Oral > Solid: 25 mg; 12.5 mg
IndicationsSectionMedicines used in heart failure- Oral > Liquid: 50 mg per 5 mL
- Oral > Solid: 25 mg
IndicationsSectionDiuretics- Oral > Solid: 25 mg
Indications -
Hydrocortisone Informations générales
SectionHormones and antihormones- Parenteral > General injections > unspecified: 100 mg in vial (as sodium succinate)
SectionAdrenal hormones and synthetic substitutes- Oral > Solid: 5 mg; 10 mg; 20 mg
IndicationsSectionOphthalmological preparations > Anti-inflammatory agents- Local > Ophthalmological > Ointment: 1% (acetate)
IndicationsSectionAntiallergics and medicines used in anaphylaxis- Parenteral > General injections > unspecified: 100 mg in vial powder for injection (as sodium succinate)
IndicationsSectionAnti-inflammatory medicines- Local > Rectal > Suppository: 25 mg (acetate)
- Local > Rectal > Retention enema: 100 mg per 60 mL
IndicationsSectionDermatological medicines > Anti-inflammatory and antipruritic medicines- Local > Topical > Cream: 1% (acetate)
- Local > Topical > Ointment: 1% (acetate)
-
Hydromorphone Informations générales
-
Hydroxocobalamin Informations générales
SectionAntianaemia medicines- Parenteral > General injections > IM: 1 mg per mL in 1 mL ampoule (as acetate); 1 mg per mL in 1 mL ampoule (as hydrochloride); 1 mg per mL in 1 mL ampoule (as sulfate)
-
Hydroxycarbamide (hydroxyurea) Informations générales
SectionCytotoxic medicines- Oral > Solid > dosage form: 200 mg; 300 mg; 400 mg; 500 mg; 1 g; 100 mg
- Oral > Solid: 200 mg; 250 mg; 300 mg; 400 mg; 500 mg; 1 g
SectionOther medicines for haemoglobinopathies- Oral > Solid > dosage form: 200 mg; 500 mg; 1 g; 100 mg
-
Hydroxychloroquine Informations générales
SectionAntimalarial medicines > For chemopreventionIndicationsTherapeutic equivalent to chloroquine pour Malaria due to Plasmodium falciparumSectionDisease-modifying anti-rheumatic drugs (DMARDs)- Oral > Solid: 200 mg (as sulfate)
-
Hyoscine butylbromide Informations générales
SectionMedicines for other common symptoms in palliative care- Parenteral > General injections > unspecified: 20 mg per mL injection
Indications -
Hyoscine hydrobromide Informations générales
SectionMedicines for other common symptoms in palliative care- Local > Topical > Transdermal patch: 1 mg per 72 hours transdermal patch
- Parenteral > General injections > unspecified: 400 µg per mL injection; 600 µg per mL injection
Indications -
Hypochlorous acid Informations générales
SectionAntiseptics- Local > Topical > Solution:
Indications -
Hypromellose Informations générales
SectionOphthalmological preparations- Local > Ophthalmological > Solution (eye drops): 0.3%
Indications -
Ibrutinib Informations générales
SectionTargeted therapies- Oral > Solid: 140 mg
-
Ibuprofen Informations générales
SectionMedicines administered to the neonate [c]- Parenteral > General injections > IV: 5 mg per mL
IndicationsSectionNon-opioids and non-steroidal anti-inflammatory medicines (NSAIMs)- Oral > Liquid: 200 mg per 5 mL; 100 mg per 5 mL
- Oral > Solid > tablet: 200 mg; 400 mg; 600 mg
IndicationsSectionAntimigraine medicines > For treatment of acute attack- Oral > Liquid: 100 mg per 5 mL; 200 mg per 5 mL
- Oral > Solid > tablet: 200 mg; 400 mg
Indications -
Idoxuridine Informations générales
SectionOphthalmological preparations > Anti-infective agents- Local > Ophthalmological > Solution (eye drops): 0.1%
- Local > Ophthalmological > Ointment: 0.2%
Indications -
Ifosfamide Informations générales
SectionCytotoxic medicines- Parenteral > General injections > IV: 500 mg in vial powder for injection; 1 g in vial powder for injection; 2 g in vial powder for injection
- Parenteral > General injections > IV: 1 g in vial powder for injection; 2 g in vial powder for injection
IndicationsOther specified malignant neoplasms of the ovary Germ cell tumour of testis Ewing sarcoma of bone and articular cartilage of unspecified sites Osteosarcoma of bone and articular cartilage of unspecified sites Rhabdomyosarcoma primary site Unspecified malignant neoplasms of ill-defined or unspecified sites Burkitt lymphoma including Burkitt leukaemia Malignant neoplasms of kidney, except renal pelvis Anaplastic large cell lymphoma, ALK-negative Anaplastic large cell lymphoma, ALK-positive -
Imatinib Informations générales
SectionTargeted therapies- Oral > Solid: 100 mg; 400 mg
-
Imipenem + cilastatin Informations générales
SectionWatch group antibiotics- Parenteral > General injections > IV: 250 mg (as monohydrate) + 250 mg (as sodium salt) powder for injection; 500 mg (as monohydrate) + 500 mg (as sodium salt) powder for injection
IndicationsSecond choix
Therapeutic equivalent to meropenem pour Neutropenia (high-risk) Therapeutic equivalent to meropenem pour Peritoneal abscess (severe) Therapeutic equivalent to meropenem pour Peritonitis (severe)Autres indicationsSectionAntituberculosis medicinesIndicationsTherapeutic equivalent to meropenem pour Multi-drug resistant Mycobacterium tuberculosis -
Imipenem + cilastatin + relebactam Informations générales
SectionReserve group antibiotics- Parenteral > General injections > IV: 500 mg + 500 mg + 250 mg powder for injection
-
Indapamide Informations générales
SectionAntihypertensive medicinesIndicationsTherapeutic equivalent to hydrochlorothiazide pour Essential hypertensionSectionMedicines used in heart failureIndicationsTherapeutic equivalent to hydrochlorothiazide pour Heart failure -
Indinavir Informations générales
SectionAntiretrovirals > Protease inhibitors- Oral > Solid: 400 mg (as sulfate)
-
Indometacin Informations générales
SectionMedicines administered to the neonate [c]IndicationsTherapeutic equivalent to ibuprofen pour Patent arterial duct -
Infliximab Informations générales
SectionImmunomodulators for non-malignant diseaseIndicationsTherapeutic equivalent to adalimumab pour Axial spondyloarthritis Therapeutic equivalent to adalimumab pour Crohn disease site Therapeutic equivalent to adalimumab pour Rheumatoid arthritisSectionMedicines for juvenile joint diseasesIndicationsTherapeutic equivalent to adalimumab pour Juvenile idiopathic arthritis -
Influenza vaccine (seasonal) Informations générales
SectionRecommendations for immunization programmes with certain characteristics- All vaccines should comply with the WHO requirements for biological substances.
Indications -
Insulin Informations générales
SectionInsulins- Parenteral > General injections > SC: 40 IU per mL in 10 mL vial (soluble); 100 IU per mL in 10 mL vial (soluble); 100 IU per mL in 3 mL cartridge (soluble); 100 IU per mL in 3 mL pre-filled pen (soluble)
Indications -
Insulin analogues Informations générales
SectionInsulins- Not specified
Indications -
Insulin degludec Informations générales
SectionInsulins- Parenteral > General injections > SC: 100 units per mL
IndicationsTherapeutic equivalent to insulin glargine pour Type 1 diabetes mellitus Therapeutic equivalent to long-acting insulin analogues pour Type 1 diabetes mellitus Therapeutic equivalent to long-acting insulin analogues pour Type 2 diabetes mellitus -
Insulin detemir Informations générales
SectionInsulinsIndicationsTherapeutic equivalent to insulin glargine pour Type 1 diabetes mellitus Therapeutic equivalent to long-acting insulin analogues pour Type 1 diabetes mellitus Therapeutic equivalent to long-acting insulin analogues pour Type 2 diabetes mellitus -
Insulin glargine Informations générales
SectionInsulins- Parenteral > General injections > SC: 100 units per mL
IndicationsType 1 diabetes mellitus Therapeutic equivalent to long-acting insulin analogues pour Type 1 diabetes mellitus Therapeutic equivalent to long-acting insulin analogues pour Type 2 diabetes mellitus -
Intermediate-acting insulin Informations générales
SectionInsulins- Parenteral > General injections > SC: 40 IU per mL in 10 mL vial as compound insulin zinc suspension or isophane insulin; 100 IU per mL in 10 mL vial as compound insulin zinc suspension or isophane insulin; 100 IU per mL in 3 mL cartridge as compound insulin zinc suspension or isophane insulin; 100 IU per mL in 3 mL pre-filled pen as compound insulin zinc suspension or isophane insulin
Indications -
Intraperitoneal dialysis solution Informations générales
SectionPeritoneal dialysis solution- parenteral solution
Indications -
Iodine Informations générales
SectionVitamins and minerals- Parenteral > General injections > IM: 0.5 mL (240 mg iodine) iodized oil in ampoule; 1 mL (480 mg iodine) iodized oil in ampoule
- Oral > Liquid: 1 mL (480 mg iodine) iodized oil in ampoule; 0.5 mL (240 mg iodine) iodized oil in ampoule; 0.57 mL (308 mg iodine) iodized oil in dispenser bottle
- Oral > Solid: 190 mg
IndicationsSectionAntisepticsIndicationsTherapeutic equivalent to povidone iodine pour Povidone iodine -
Iohexol Informations générales
SectionDiagnostic agents > Radiocontrast media- Parenteral > General injections > unspecified: 140 to 350 mg iodine per mL in 5 mL ampoule; 140 to 350 mg iodine per mL in 10 mL ampoule; 140 to 350 mg iodine per mL in 20 mL ampoule
Indications -
Ipecacuanha Informations générales
SectionAntidotes and other substances used in poisonings > Non-specific- Oral > Liquid: 0.14% ipecacuanha alkaloids calculated as emetine
-
Ipratropium bromide Informations générales
SectionAntiasthmatic and medicines for chronic obstructive pulmonary disease- Respiratory > Inhalation > aerosol: 20 µg per dose
Indications -
Irinotecan Informations générales
SectionCytotoxic medicines- Parenteral > General injections > IV: 40 mg per 2 mL in 2 mL vial; 100 mg per 5 mL in 5 mL vial; 500 mg per 25 mL in 25 mL vial
-
Isoflurane Informations générales
SectionGeneral anaesthetics and oxygen > Inhalational medicines- Respiratory > Inhalation > liquid:
Indications -
Isoniazid Informations générales
SectionAntituberculosis medicines- Parenteral > General injections > IV: 100 mg per mL
- Oral > Solid > dispersible tablet: 100 mg
- Oral > Solid > tablet: 100 mg; 300 mg
Indications -
Isoniazid + pyrazinamide + rifampicin Informations générales
SectionAntituberculosis medicines- Oral > Solid > dispersible tablet: 50 mg + 150 mg + 75 mg
Indications -
Isoniazid + pyridoxine + sulfamethoxazole + trimethoprim Informations générales
SectionMedicines for prevention of HIV-related opportunistic infections- Oral > Solid: 300 mg + 25 mg + 800 mg + 160 mg tablet (scored)
Indications -
Isoniazid + rifampicin Informations générales
SectionAntituberculosis medicines- Oral > Solid > dispersible tablet: 50 mg + 75 mg
- Oral > Solid > tablet: 75 mg + 150 mg; 150 mg + 300 mg
Indications -
Isoniazid + rifapentine Informations générales
SectionAntituberculosis medicines- Oral > Solid: 300 mg + 300 mg tablet (scored)
Indications -
Isoprenaline Informations générales
SectionAntiarrhythmic medicines- Parenteral > General injections > IV: 20 µg per mL in ampoule (hydrochloride)
- Oral > Solid: 10 mg (hydrochloride or sulfate); 15 mg (hydrochloride or sulfate)
Indications -
Isosorbide dinitrate Informations générales
SectionAntianginal medicines- Oral > Solid: 5 mg sublingual tablet
Indications -
Itraconazole Informations générales
SectionAntifungal medicines- Oral > Liquid: 10 mg per mL
- Oral > Solid: 100 mg
-
Ivermectin Informations générales
SectionIntestinal anthelminthics- Oral > Solid > tablet: 3 mg
SectionAntifilarials- Oral > Solid > tablet: 3 mg
IndicationsSectionMedicines for ectoparasitic infections- Oral > Solid > tablet: 3 mg
Indications -
Kanamycin Informations générales
SectionOphthalmological preparations > Anti-infective agentsIndicationsTherapeutic equivalent to gentamicin pour Other specified conjunctivitis Therapeutic equivalent to gentamicin pour Infectious blepharitis -
Kanamycin (injection) Informations générales
SectionAntituberculosis medicines- Parenteral > General injections > IV: 1000 mg powder for injection (vial)
Indications -
Ketamine Informations générales
SectionGeneral anaesthetics and oxygen > Injectable medicines- Parenteral > General injections > unspecified: 50 mg per mL in 10 mL vial (as hydrochloride)
Indications -
Ketoconazole Informations générales
SectionMedicines for endocrine disorders- Oral > Solid > tablet: 200 mg
Indications -
Lactulose Informations générales
SectionMedicines for other common symptoms in palliative care- Oral > Liquid: 3.1 to 3.7 g per 5 mL oral liquid
Indications -
Lamivudine Informations générales
SectionAntiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors- Oral > Liquid: 50 mg per 5 mL
- Oral > Solid: 150 mg tablet
-
Lamivudine + nevirapine + zidovudine Informations générales
SectionFixed-dose combinations of antiretrovirals- Oral > Solid: 30 mg + 50 mg + 60 mg Tablet; 150 mg + 200 mg + 300 mg Tablet
-
Lamivudine + tenofovir Informations générales
SectionFixed-dose combinations of antiretroviralsIndicationsTherapeutic equivalent to emtricitabine + tenofovir pour Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified Therapeutic equivalent to emtricitabine + tenofovir pour Contact with or exposure to human immunodeficiency virus -
Lamivudine + zidovudine Informations générales
SectionFixed-dose combinations of antiretrovirals- Oral > Solid: 30 mg + 60 mg Tablet; 150 mg + 300 mg Tablet
-
Lamotrigine Informations générales
SectionAntiseizure medicines- Oral > Solid: 25 mg tablet; 50 mg tablet; 100 mg tablet; 200 mg tablet; 2 mg tablet (chewable, dispersible); 5 mg tablet (chewable, dispersible); 25 mg tablet (chewable, dispersible); 50 mg tablet (chewable, dispersible); 100 mg tablet (chewable, dispersible); 200 mg tablet (chewable, dispersible)
Indications -
Latanoprost Informations générales
SectionOphthalmological preparations > Miotics and antiglaucoma medicines- Local > Ophthalmological > Solution (eye drops): 50 µg per mL eye drops
Indications -
Ledipasvir + sofosbuvir Informations générales
SectionMedicines for hepatitis C > Non-pangenotypic direct-acting antiviral combinations- Oral > Solid: 90 mg + 400 mg tablet
Indications -
Lenalidomide Informations générales
SectionImmunomodulators- Oral > Solid: 25 mg
Indications -
Letrozole Informations générales
SectionOvulation inducers- Oral > Solid > dosage form: 2.5 mg
-
Leuprorelin Informations générales
SectionHormones and antihormones- Parenteral > General injections > IM: 7.5 mg in prefilled syringe; 22.5 mg in prefilled syringe
-
Levamisole Informations générales
SectionIntestinal anthelminthics- Oral > Solid > tablet: 50 mg (as hydrochloride); 150 mg (as hydrochloride)
Indications -
Levetiracetam Informations générales
SectionAntiseizure medicines- Oral > Liquid: 100 mg per mL
- Oral > Solid > tablet: 250 mg; 500 mg; 750 mg; 1000 mg
- Parenteral > General injections > IV: 500 mg per 5 mL in 5 mL vial; 5 mg per mL in 100 mL bag; 10 mg per mL in 100 mL bag; 15 mg per mL in 100 mL bag
Indications -
Levodopa Informations générales
SectionAntiseizure medicines- Oral > Solid: 250 mg
Indications -
Levodopa + benserazide Informations générales
SectionMedicines for parkinsonismIndicationsTherapeutic equivalent to levodopa + carbidopa pour Parkinson disease -
Levodopa + carbidopa Informations générales
SectionMedicines for parkinsonism- Oral > Solid: 100 mg + 10 mg tablet; 250 mg + 25 mg tablet; 100 mg + 25 mg tablet
Indications -
Levofloxacin Informations générales
SectionAntituberculosis medicines- Oral > Solid > dispersible tablet: 100 mg
- Oral > Solid > tablet: 250 mg; 500 mg; 750 mg
Indications -
Levonorgestrel Informations générales
SectionOral hormonal contraceptives- Oral > Solid: 750 µg [2]; 1.5 mg [1]
- Oral > Solid: 30 µg
SectionIntrauterine devices- Intrauterine system with reservoir containing 52 mg of levonorgestrel.
-
Levonorgestrel-releasing implant Informations générales
SectionImplantable contraceptives- Implant > Subdermal: 75 mg per rod (two-rods)
-
Levothyroxine Informations générales
SectionThyroid hormones and antithyroid medicines- Oral > Solid: 50 µg (sodium salt); 100 µg (sodium salt); 25 µg (sodium salt)
Indications -
Lidocaine Informations générales
SectionAntiarrhythmic medicines- Parenteral > General injections > IV: 20 mg per mL in 5 mL ampoule (hydrochloride)
IndicationsSectionLocal anaesthetics- Parenteral > Locoregional injections > Spinal anaesthesia: 5% in 2 mL ampoule (hydrochloride) + 7.5% glucose solution
- Parenteral > Locoregional injections > Other: 1% in vial (hydrochloride); 2% in vial (hydrochloride)
- Local > Topical > unspecified: 2 to 4% (hydrochloride)
Indications -
Lidocaine + epinephrine Informations générales
SectionLocal anaesthetics- Parenteral > Locoregional injections > Other: 1% (lidocaine hydrochloride OR lidocaine sulfate) + 1:200 000 epinephrine in vial; 2% (lidocaine hydrochloride OR lidocaine sulfate) + 1:200 000 epinephrine in vial
- Local > Dental > Cartridge: 2% (lidocaine hydrochloride) + 1:80 000 epinephrine
Indications -
Lindane Informations générales
SectionDermatological medicines > Scabicides and pediculicides- Local > Topical > Cream: 1%
- Local > Topical > Lotion: 1%
Indications -
Linezolid Informations générales
SectionReserve group antibiotics- Parenteral > General injections > IV: 2 mg per mL in 300 mL bag
- Oral > Liquid: 100 mg per 5 mL powder for oral liquid
- Oral > Solid: 400 mg tablet; 600 mg tablet
- Oral > Solid > dispersible tablet: 150 mg
- Oral > Solid > tablet: 600 mg
SectionAntituberculosis medicines- Oral > Solid > dispersible tablet: 150 mg
- Oral > Solid > tablet: 600 mg
Indications -
Liraglutide Informations générales
SectionMedicines for endocrine disorders- Parenteral > General injections > SC: 6 mg per mL in 3 mL pre-filled pen
Indications -
Lisinopril + amlodipine Informations générales
SectionAntihypertensive medicines- Oral > Solid: 10 mg + 5 mg; 20 mg + 5 mg; 20 mg + 10 mg
Indications -
Lisinopril + hydrochlorothiazide Informations générales
SectionAntihypertensive medicines- Oral > Solid: 10 mg + 12.5 mg; 20 mg + 12.5 mg; 20 mg + 25 mg
Indications -
Lisocabtagene maraleucel Informations générales
SectionAntineoplastics and supportive medicinesIndicationsTherapeutic equivalent to axicabtagene ciloleucel pour Diffuse large B-cell lymphomas -
Lithium carbonate Informations générales
SectionMedicines for bipolar disorders- Oral > Solid: 300 mg
Indications -
Long-acting insulin analogues Informations générales
SectionInsulins- Parenteral > General injections > SC: 100 IU per mL in 3 mL cartridge; 100 IU per mL in 3 mL pre-filled pen
Indications -
Loperamide Informations générales
SectionMedicines for other common symptoms in palliative care- Oral > Solid > dosage form: 2 mg
Indications -
Lopinavir + ritonavir Informations générales
SectionAntiretrovirals > Protease inhibitors- Oral > Solid > tablet: 100 mg + 25 mg tablet (heat-stable); 200 mg + 50 mg tablet (heat-stable)
- Oral > Solid > dosage form: 40 mg + 10 mg
-
Loratadine Informations générales
SectionAntiallergics and medicines used in anaphylaxis- Oral > Liquid: 1 mg per mL
- Oral > Solid: 10 mg
-
Lorazepam Informations générales
SectionAntiseizure medicines- Parenteral > General injections > IV: 2 mg per mL in 1 mL ampoule; 4 mg per mL in 1 mL ampoule
Indications -
Losartan Informations générales
SectionAntihypertensive medicines- Oral > Solid: 25 mg tablet; 50 mg tablet; 100 mg tablet
IndicationsSectionMedicines used in heart failure- Oral > Solid: 25 mg tablet; 50 mg tablet; 100 mg tablet
Indications -
Lovastatin Informations générales
SectionLipid-lowering agentsIndicationsTherapeutic equivalent to simvastatin pour Mixed hyperlipidaemia Therapeutic equivalent to simvastatin pour Coronary atherosclerosis -
Lugol's solution Informations générales
SectionThyroid hormones and antithyroid medicines- Oral > Liquid: 13% w/v (about 130 mg/mL total iodine)
Indications -
Magnesium sulfate Informations générales
SectionAntiseizure medicines- Parenteral > General injections > IV: 500 mg per mL in 2 mL ampoule (equivalent to 1 g in 2 mL; 50% weight/volume)
- Parenteral > General injections > IM: 500 mg per mL in 10 mL ampoule (equivalent to 5 g in 10 mL; 50% weight/volume)
Indications -
Mannitol Informations générales
SectionDiuretics- Parenteral > General injections > IV: 10% solution; 20% solution
Indications -
Measles vaccine Informations générales
SectionRecommendations for all immunization programmes- All vaccines should comply with the WHO requirements for biological substances.
Indications -
Mebendazole Informations générales
SectionIntestinal anthelminthics- Oral > Solid > tablet: 100 mg (chewable); 500 mg (chewable)
IndicationsSectionCysticidal medicines- Oral > Solid > tablet: 100 mg (chewable); 500 mg (chewable)
Indications -
Medroxyprogesterone acetate Informations générales
SectionInjectable hormonal contraceptives- Parenteral > General injections > IM: 150 mg per mL in 1 mL vial
- Parenteral > General injections > SC: 104 mg per 0.65 mL in pre-filled syringe; 104 mg per 0.65 mL in single dose injection delivery system
SectionProgestogens- Oral > Solid: 5 mg
Indications -
Mefloquine Informations générales
SectionAntimalarial medicines > For curative treatment- Oral > Solid: 250 mg tablet (hydrochloride)
SectionAntimalarial medicines > For chemoprevention- Oral > Solid: 250 mg tablet (hydrochloride)
Indications -
Meglumine antimoniate Informations générales
SectionAntileishmaniasis medicines- Parenteral > General injections > IM: 1.5 g per 5 mL in 5 mL ampoule
-
Meglumine iotroxate Informations générales
SectionDiagnostic agents > Radiocontrast media- Parenteral > General injections > IV: 5 to 8 g iodine (as meglumine) in 100 to 250 mL
Indications -
Melarsoprol Informations générales
SectionMedicines for the treatment of 2nd stage African trypanosomiasis- Parenteral > General injections > IV: 3.6% in 5 mL ampoule solution (180 mg of active compound)
Indications -
Melphalan Informations générales
SectionCytotoxic medicines- Parenteral > General injections > IV: 50 mg in vial powder for injection
- Oral > Solid: 2 mg
Indications -
Meningococcal meningitis vaccine Informations générales
SectionRecommendations for some high-risk populations- All vaccines should comply with the WHO requirements for biological substances.
-
Mercaptopurine Informations générales
SectionCytotoxic medicines- Oral > Solid: 50 mg tablet
- Oral > Liquid: 20 mg per mL
-
Meropenem Informations générales
SectionWatch group antibiotics- Parenteral > General injections > IV: 500 mg in vial (as trihydrate) powder for injection; 1 g in vial (as trihydrate) powder for injection
IndicationsSectionAntituberculosis medicines- Parenteral > General injections > IV: 500 mg in vial (as trihydrate) powder for injection; 1 g in vial (as trihydrate) powder for injection
Indications -
Meropenem + vaborbactam Informations générales
SectionReserve group antibiotics- Parenteral > General injections > IV: 1 g in vial + 1 g in vial powder for injection
-
Mesalazine Informations générales
SectionAnti-inflammatory medicinesIndicationsTherapeutic equivalent to sulfasalazine pour Crohn disease site Therapeutic equivalent to sulfasalazine pour Ulcerative colitis -
Mesna Informations générales
SectionSupportive medicines- Parenteral > General injections > IV: 100 mg per mL in 4 mL ampoule; 100 mg per mL in 10 mL ampoule
- Oral > Solid: 400 mg; 600 mg
IndicationsOsteosarcoma of bone and articular cartilage of other specified sites Other specified malignant neoplasms of the ovary Germ cell tumour of testis Ewing sarcoma of bone and articular cartilage of unspecified sites Rhabdomyosarcoma primary site Unspecified malignant neoplasms of ill-defined or unspecified sites Burkitt lymphoma including Burkitt leukaemia Malignant neoplasms of kidney, except renal pelvis -
Metformin Informations générales
SectionOral hypoglycaemic agents- Oral > Solid: 500 mg (hydrochloride)
Indications -
Methadone Informations générales
SectionMedicines for opioid use disorders- Oral > Liquid: 5 mg per 5 mL (methadone hydrochloride); 10 mg per 5 mL (methadone hydrochloride); 5 mg per mL concentrate for oral liquid (methadone hydrochloride); 10 mg per mL concentrate for oral liquid (methadone hydrochloride)
IndicationsSectionOpioid analgesics- Oral > Liquid: 5 mg per 5 mL (methadone hydrochloride); 10 mg per 5 mL (methadone hydrochloride); 5 mg per mL concentrate for oral liquid (methadone hydrochloride); 10 mg per mL concentrate for oral liquid (methadone hydrochloride)
- Oral > Solid: 5 mg (methadone hydrochloride); 10 mg (methadone hydrochloride)
Indications -
Methimazole Informations générales
SectionThyroid hormones and antithyroid medicines- Oral > Solid: 5 mg; 10 mg; 20 mg
Indications -
Methionine Informations générales
SectionAntidotes and other substances used in poisonings > Specific- Oral > Solid: 250 mg (DL)
-
Methotrexate Informations générales
SectionCytotoxic medicines- Parenteral > General injections > IV: 50 mg in vial (as sodium salt)
- Oral > Solid: 2.5 mg (as sodium salt)
- Parenteral > General injections > IV: 50 mg in vial (as sodium salt); 50 mg per 2 mL; 1000 mg per 10 mL concentrated injection
IndicationsUnspecified malignant neoplasms of ill-defined or unspecified sites Lymphoid leukaemia, not elsewhere classified Acute myeloid leukaemia with recurrent genetic abnormalities Malignant trophoblastic neoplasms of placenta Burkitt lymphoma including Burkitt leukaemia Malignant neoplasms of breast Osteosarcoma of bone and articular cartilage of unspecified sites Anaplastic large cell lymphoma, ALK-negative Anaplastic large cell lymphoma, ALK-positive Langerhans cell histiocytosisSectionDermatological medicines > Medicines affecting skin differentiation and proliferation- Oral > Solid > tablet: 2.5 mg (as sodium salt); 10 mg (as sodium salt)
IndicationsSectionDisease-modifying anti-rheumatic drugs (DMARDs)- Oral > Solid > tablet: 2.5 mg (as sodium salt)
IndicationsSectionImmunomodulators for non-malignant disease- Parenteral > General injections > SC: pre-filled syringe in multiple strengths
IndicationsSectionMedicines for juvenile joint diseases- Oral > Solid > tablet: 2.5 mg (as sodium salt)
Indications -
Methoxy polyethylene glycol-epoetin beta Informations générales
SectionAntianaemia medicinesIndicationsTherapeutic equivalent to erythropoiesis-stimulating agents pour Anaemia due to chronic disease -
Methyldopa Informations générales
SectionAntihypertensive medicines- Oral > Solid: 250 mg
Indications -
Methylergometrine Informations générales
SectionUterotonicsIndicationsTherapeutic equivalent to ergometrine pour Postpartum haemorrhage -
Methylphenidate Informations générales
SectionMedicines for mental and behavioural disorders- Multiple formulations and strengths.
Indications -
Methylprednisolone Informations générales
SectionHormones and antihormones- Parenteral > General injections > IV: 40 mg per mL in 1 mL single-dose vial (as sodium succinate); 40 mg per mL in 5 mL multi-dose vial (as sodium succinate); 80 mg per mL in 1 mL single-dose vial (as sodium succinate)
-
Methylthioninium chloride Informations générales
SectionAntidotes and other substances used in poisonings > Specific- Parenteral > General injections > IV: 10 mg per mL in 10 mL ampoule
Indications -
Metoclopramide Informations générales
SectionMedicines for other common symptoms in palliative care- Oral > Liquid: 5 mg per 5 mL
- Oral > Solid: 10 mg (hydrochloride)
- Parenteral > General injections > unspecified: 5 mg per mL in 2 mL ampoule (hydrochloride)
IndicationsSectionAntiemetic medicines- Oral > Liquid: 5 mg per 5 mL
- Oral > Solid: 10 mg (hydrochloride)
- Parenteral > General injections > unspecified: 5 mg per mL in 2 mL ampoule (hydrochloride)
Indications -
Metoprolol Informations générales
SectionAntianginal medicinesIndicationsTherapeutic equivalent to bisoprolol pour Angina pectorisSectionMedicines used in heart failureIndicationsTherapeutic equivalent to bisoprolol pour Heart failureSectionAntihypertensive medicinesIndicationsTherapeutic equivalent to bisoprolol pour Essential hypertensionSectionAntiarrhythmic medicinesIndicationsTherapeutic equivalent to bisoprolol pour Cardiac arrhythmia -
Metronidazole Informations générales
SectionAccess group antibiotics- Oral > Liquid: 200 mg per 5 mL (as benzoate)
- Oral > Solid: 200 to 500 mg tablet
- Parenteral > General injections > unspecified: 500 mg per 100 mL in vial Injection
- Local > Rectal > Suppository: 500 mg; 1 g
- Parenteral > General injections > unspecified: 500 mg per 100 mL in vial
- Oral > Solid > tablet: 200 mg; 250 mg; 400 mg; 500 mg
IndicationsPremier choix
Intestinal infections due to Clostridioides difficile Trichomoniasis co-prescrite avec cefazolin Other specified prophylactic measures co-prescrite avec cefotaxime Peritonitis (severe) co-prescrite avec cefotaxime Peritonitis (mild-moderate) co-prescrite avec cefotaxime Peritoneal abscess (mild-moderate) co-prescrite avec cefotaxime Peritoneal abscess (severe) co-prescrite avec ceftriaxone Necrotising fasciitis co-prescrite avec ceftriaxone Peritonitis (severe) co-prescrite avec ceftriaxone Peritoneal abscess (mild-moderate) co-prescrite avec ceftriaxone Peritoneal abscess (severe) co-prescrite avec ceftriaxone Peritonitis (mild-moderate)Second choix
co-prescrite avec ciprofloxacin Peritonitis (mild-moderate) co-prescrite avec ciprofloxacin Peritoneal abscess (mild-moderate)Autres indicationsSectionAntiamoebic and antigiardiasis medicines- Oral > Liquid: 200 mg per 5 mL (as benzoate)
- Parenteral > General injections > unspecified: 500 mg in 100 mL vial
- Oral > Solid > tablet: 200 mg; 250 mg; 400 mg; 500 mg
Indications -
Micafungin Informations générales
SectionAntifungal medicines- Parenteral > General injections > IV: 50 mg in vial (as sodium) powder for injection; 100 mg in vial (as sodium) powder for injection
Indications -
Miconazole Informations générales
SectionDermatological medicines > Antifungal medicines- Local > Topical > Cream: 2% (nitrate)
- Local > Topical > Ointment: 2% (nitrate)
Indications -
Midazolam Informations générales
SectionAntiseizure medicines- Parenteral > General injections > unspecified: 1 mg per mL in 5 mL vial (for buccal administration); 5 mg per mL in 1 mL vial (for buccal administration); 5 mg per mL in 3 mL vial (for buccal administration)
- Local > Buccal > Solution: 5 mg per mL in 0.5 mL pre-filled syringe (for oromucosal administration); 5 mg per mL in 1 mL pre-filled syringe (for oromucosal administration); 5 mg per mL in 1.5 mL pre-filled syringe (for oromucosal administration); 5 mg per mL in 2 mL pre-filled syringe (for oromucosal administration); 10 mg per mL in 0.25 mL pre-filled syringe (for oromucosal administration); 10 mg per mL in 0.5 mL pre-filled syringe (for oromucosal administration); 10 mg per mL in 0.75 mL pre-filled syringe; 10 mg per mL in 1 mL pre-filled syringe (for oromucosal administration)
IndicationsSectionPreoperative medication and sedation for short-term procedures- Parenteral > General injections > IV: 1 mg per mL
- Oral > Liquid: 2 mg per mL
- Oral > Solid > dosage form: 15 mg; 7.5 mg
IndicationsSectionMedicines for other common symptoms in palliative care- Oral > Liquid: 2 mg per mL
- Parenteral > General injections > unspecified: 1 mg per mL; 5 mg per mL
- Oral > Solid > dosage form: 7.5 mg; 15 mg
Indications -
Mifepristone - misoprostol Informations générales
SectionUterotonics- Oral > Solid: 200 mg + 200 µg; 200 mg [1] + 200 µg [4] in co-package
-
Miltefosine Informations générales
SectionAntileishmaniasis medicines- Oral > Solid: 10 mg; 50 mg
-
Misoprostol Informations générales
SectionUterotonics- Oral > Solid: 200 µg
- Local > Vaginal > tablet: 25 µg
-
Mometasone Informations générales
SectionAntiasthmatic and medicines for chronic obstructive pulmonary diseaseIndicationsTherapeutic equivalent to budesonide pour Asthma -
Mometasone + formoterol Informations générales
SectionAntiasthmatic and medicines for chronic obstructive pulmonary diseaseIndicationsTherapeutic equivalent to budesonide + formoterol pour Asthma -
Morphine Informations générales
SectionOpioid analgesics- Oral > Liquid: 10 mg per 5 mL (morphine hydrochloride or morphine sulfate)
- Oral > Solid: 10 mg immediate release (morphine sulfate); 10 to 200 mg slow release (morphine hydrochloride or morphine sulfate)
- Oral > Other: 20 to 200 mg slow release granules to mix with water (morphine sulfate)
- Parenteral > General injections > unspecified: 10 mg in 1 mL ampoule (morphine hydrochloride or morphine sulfate)
IndicationsSectionPreoperative medication and sedation for short-term procedures- Parenteral > General injections > IV: 10 mg in 1 mL ampoule (morphine hydrochloride or morphine sulfate)
-
Moxifloxacin Informations générales
SectionAntituberculosis medicines- Oral > Solid > dispersible tablet: 100 mg
- Oral > Solid > tablet: 400 mg
-
Multiple micronutrient powder Informations générales
SectionVitamins and minerals- Sachets containing:
- - iron (elemental) 12.5 mg (as coated ferrous fumarate)
- - zinc (elemental) 5 mg
- - vitamin A 300 micrograms
- - with or without other micronutrients at recommended daily values
Indications -
Multiple micronutrient supplement Informations générales
SectionOther medicines administered to the mother- Tablet containing:
- Vit A: 800 mcg retinol activity equivalent
- Vit C: 70 mg
- Vit D: 5 mcg (200 IU)
- Vit E: 10 mg alpha tocopherol equivalent
- Vit B1: 1.4 mg
- Vit B2: 1.4 mg
- Vit B3: 18 mg niacin equivalent
- Vit B6: 1.9 mg
- Folic acid: 400 mcg
- Vit B12: 2.6 mcg
- Iron: 30 mg
- Iodine: 150 mcg
- Zinc: 15 mg
- Selenium: 65 mcg
- Copper: 2 mg
-
Mumps vaccine Informations générales
SectionRecommendations for immunization programmes with certain characteristics- All vaccines should comply with the WHO requirements for biological substances.
Indications -
Mupirocin Informations générales
SectionDermatological medicines > Anti-infective medicines- Local > Topical > Cream: 2% (as mupirocin calcium)
- Local > Topical > Ointment: 2%
Indications -
Nadroparin Informations générales
SectionMedicines affecting coagulationIndicationsTherapeutic equivalent to enoxaparin pour Acute ischaemic heart disease Therapeutic equivalent to enoxaparin pour Venous thromboembolism -
Nalidixic acid Informations générales
SectionAnti-infective medicines- Oral > Solid: 250 mg; 500 mg
Indications -
Naloxone Informations générales
SectionAntidotes and other substances used in poisonings > Specific- Parenteral > General injections > unspecified: 400 µg per 1 mL in ampoule (naloxone hydrochloride)
-
Naltrexone Informations générales
SectionMedicines for alcohol use disorders- Parenteral > General injections > IM: 380 mg in vial (extended-release)
- Oral > Solid > tablet: 50 mg
Indications -
Natamycin Informations générales
SectionOphthalmological preparations > Anti-infective agents- Local > Ophthalmological > Suspension: 5% eye drops
Indications -
Nelfinavir Informations générales
SectionAntiretrovirals > Protease inhibitors- Oral > Solid: 250 mg (as mesilate)
- Oral > Other: 50 mg per g oral powder
-
Neostigmine Informations générales
SectionMuscle relaxants (peripherally-acting) and cholinesterase inhibitors- Oral > Solid: 15 mg (neostigmine bromide)
- Parenteral > General injections > unspecified: 0.5 mg per mL in 1 mL ampoule (neostigmine metilsulfate); 2.5 mg per mL in 1 mL ampoule (neostigmine metilsulfate)
Indications -
Netilmicin Informations générales
SectionOphthalmological preparations > Anti-infective agentsIndicationsTherapeutic equivalent to gentamicin pour Other specified conjunctivitis Therapeutic equivalent to gentamicin pour Infectious blepharitis -
Nevirapine Informations générales
SectionAntiretrovirals > Non-nucleoside reverse transcriptase inhibitors- Oral > Liquid: 50 mg per 5 mL
- Oral > Solid > dispersible tablet: 50 mg
- Oral > Solid > tablet: 200 mg
-
Niclosamide Informations générales
SectionIntestinal anthelminthics- Oral > Solid: 500 mg tablet (chewable)
-
Nicotinamide Informations générales
SectionVitamins and minerals- Oral > Solid: 50 mg
Indications -
Nicotine replacement therapy Informations générales
SectionMedicines for nicotine use disorders- Local > Topical > Transdermal patch: 5 to 30 mg per 16 hour; 7 to 21 mg per 24 hour
- Oral > Solid > lozenge: 2 mg; 4 mg lozenge
- Local > Buccal > Oral spray: 1 mg per actuation
- Local > Buccal > Chewing gum: 2 mg; 4 mg
Indications -
Nifedipine Informations générales
SectionAntioxytocics (tocolytics)- Oral > Solid: 10 mg (immediate-release)
IndicationsSectionAntianginal medicines- Oral > Solid: 10 mg
IndicationsSectionAntihypertensive medicines- Oral > Solid: 10 mg tablet; sustained-release formulations
Indications -
Nifurtimox Informations générales
SectionAmerican trypanosomiasis- Oral > Solid > tablet: 30 mg (scored); 120 mg (scored)
IndicationsSectionMedicines for the treatment of 2nd stage African trypanosomiasis- Oral > Solid > tablet: 30 mg (scored); 120 mg (scored)
Indications -
Nilotinib Informations générales
SectionTargeted therapies- Oral > Solid > capsule: 150 mg; 200 mg
-
Nilutamide Informations générales
SectionHormones and antihormonesIndicationsTherapeutic equivalent to bicalutamide pour Malignant neoplasms of prostate -
Nitrofurantoin Informations générales
SectionAccess group antibiotics- Oral > Liquid: 25 mg per 5 mL oral liquid
- Oral > Solid > dosage form: 100 mg; 50 mg
-
Nitrous oxide Informations générales
SectionGeneral anaesthetics and oxygen > Inhalational medicines- Respiratory > Inhalation:
Indications -
Nivolumab Informations générales
SectionImmunomodulators- Parenteral > General injections > IV: 10 mg per mL concentrate solution for infusion
-
Norethisterone Informations générales
SectionOral hormonal contraceptives- Oral > Solid: 350 µg
SectionProgestogens- Oral > Solid: 5 mg
IndicationsExcessive menstruation with irregular cycle Therapeutic equivalent to medroxyprogesterone acetate pour Excessive menstruation with irregular cycle -
Norethisterone enantate Informations générales
SectionInjectable hormonal contraceptives- Parenteral > General injections > IM: 200 mg per mL in 1 mL ampoule oily solution
-
Normal immunoglobulin Informations générales